A hydrolase enzyme that converts L-asparagine and water to L-aspartate and NH3. EC 3.5.1.1.
Works containing information articles on subjects in every field of knowledge, usually arranged in alphabetical order, or a similar work limited to a special field or subject. (From The ALA Glossary of Library and Information Science, 1983)
Lists of words, usually in alphabetical order, giving information about form, pronunciation, etymology, grammar, and meaning.
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
A non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue. It is biosynthesized from ASPARTIC ACID and AMMONIA by asparagine synthetase. (From Concise Encyclopedia Biochemistry and Molecular Biology, 3rd ed)
A species of gram-negative, facultatively anaerobic, rod-shaped bacteria that causes vascular wilts on a wide range of plant species. It was formerly named Erwinia chrysanthemi.
A genus of gram-negative, facultatively anaerobic, rod-shaped bacteria whose organisms are associated with plants as pathogens, saprophytes, or as constituents of the epiphytic flora.
Societies whose membership is limited to pharmacists.
A group of carbon-oxygen lyases. These enzymes catalyze the breakage of a carbon-oxygen bond in polysaccharides leading to an unsaturated product and the elimination of an alcohol. EC 4.2.2.
Advanced programs of training to meet certain professional requirements in fields other than medicine or dentistry, e.g., pharmacology, nutrition, nursing, etc.
A thick-rooted perennial (Cichorium intybus) native to Europe but widely grown for its young leaves used as salad greens and for its roots, dried and ground-roasted, used to flavor or adulterate coffee. (From Webster, 3d ed)
Libraries in which a major proportion of the resources are available in machine-readable format, rather than on paper or MICROFORM.
An adenine nucleotide containing one phosphate group which is esterified to both the 3'- and 5'-positions of the sugar moiety. It is a second messenger and a key intracellular regulator, functioning as a mediator of activity for a number of hormones, including epinephrine, glucagon, and ACTH.
Any liquid or solid preparation made specifically for the growth, storage, or transport of microorganisms or other types of cells. The variety of media that exist allow for the culturing of specific microorganisms and cell types, such as differential media, selective media, test media, and defined media. Solid media consist of liquid media that have been solidified with an agent such as AGAR or GELATIN.
Proteins obtained from ESCHERICHIA COLI.
Sulfuric acid diammonium salt. It is used in CHEMICAL FRACTIONATION of proteins.
A colorless alkaline gas. It is formed in the body during decomposition of organic materials during a large number of metabolically important reactions. Note that the aqueous form of ammonia is referred to as AMMONIUM HYDROXIDE.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Immunologically mediated adverse reactions to medicinal substances used legally or illegally.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
A genus of aerobic, gram-negative bacteria in the family FLAVOBACTERIACEAE. Many of its species were formerly in the genus FLAVOBACTERIUM.
Infections with bacteria of the family FLAVOBACTERIACEAE.
A family of bacteria in the order Sphingobacteriales, class Sphingobacteria. They are gram-negative rods, mostly saprophytic in terrestrial and aquatic habitats.
A recessively inherited, progressive lysosomal storage disease caused by a deficiency of GLYCOSYLASPARAGINASE activity. The lack of this enzyme activity results in the accumulation of N-acetylglucosaminylasparagine (the linkage unit of asparagine-linked glycoproteins) in LYSOSOMES.
Carbohydrates consisting of between two (DISACCHARIDES) and ten MONOSACCHARIDES connected by either an alpha- or beta-glycosidic link. They are found throughout nature in both the free and bound form.
A spiral bacterium active as a human gastric pathogen. It is a gram-negative, urease-positive, curved or slightly spiral organism initially isolated in 1982 from patients with lesions of gastritis or peptic ulcers in Western Australia. Helicobacter pylori was originally classified in the genus CAMPYLOBACTER, but RNA sequencing, cellular fatty acid profiles, growth patterns, and other taxonomic characteristics indicate that the micro-organism should be included in the genus HELICOBACTER. It has been officially transferred to Helicobacter gen. nov. (see Int J Syst Bacteriol 1989 Oct;39(4):297-405).
Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.
A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from GLUTAMIC ACID and AMMONIA. It is the principal carrier of NITROGEN in the body and is an important energy source for many cells.
A genus of gram-negative, spiral-shaped bacteria that has been isolated from the intestinal tract of mammals, including humans. It has been associated with PEPTIC ULCER.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
Databases containing information about PROTEINS such as AMINO ACID SEQUENCE; PROTEIN CONFORMATION; and other properties.
A loose confederation of computer communication networks around the world. The networks that make up the Internet are connected through several backbone networks. The Internet grew out of the US Government ARPAnet project and was designed to facilitate information exchange.
The portion of an interactive computer program that issues messages to and receives commands from a user.
A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc.
The study of crystal structure using X-RAY DIFFRACTION techniques. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
A lysosomal cysteine proteinase with a specificity similar to that of PAPAIN. The enzyme is present in a variety of tissues and is important in many physiological and pathological processes. In pathology, cathepsin B has been found to be involved in DEMYELINATION; EMPHYSEMA; RHEUMATOID ARTHRITIS, and NEOPLASM INVASIVENESS.
ENDOPEPTIDASES which have a cysteine involved in the catalytic process. This group of enzymes is inactivated by CYSTEINE PROTEINASE INHIBITORS such as CYSTATINS and SULFHYDRYL REAGENTS.
A group of lysosomal proteinases or endopeptidases found in aqueous extracts of a variety of animal tissues. They function optimally within an acidic pH range. The cathepsins occur as a variety of enzyme subtypes including SERINE PROTEASES; ASPARTIC PROTEINASES; and CYSTEINE PROTEASES.
A ubiquitously-expressed cysteine protease that plays an enzymatic role in POST-TRANSLATIONAL PROTEIN PROCESSING of proteins within SECRETORY GRANULES.
It is a form of protection provided by law. In the United States this protection is granted to authors of original works of authorship, including literary, dramatic, musical, artistic, and certain other intellectual works. This protection is available to both published and unpublished works. (from Circular of the United States Copyright Office, 6/30/2008)
A country spanning from central Asia to the Pacific Ocean.
The profession of writing. Also the identity of the writer as the creator of a literary production.
Individuals licensed to practice medicine.
Property, such as patents, trademarks, and copyright, that results from creative effort. The Patent and Copyright Clause (Art. 1, Sec. 8, cl. 8) of the United States Constitution provides for promoting the progress of science and useful arts by securing for limited times to authors and inventors, the exclusive right to their respective writings and discoveries. (From Black's Law Dictionary, 5th ed, p1014)
Individual's rights to obtain and use information collected or generated by others.

Cerebrospinal fluid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukemia. (1/487)

PURPOSE: The CNS is an important sanctuary site in childhood acute lymphoblastic leukemia (ALL). CSF asparagine concentration reflects asparaginase systemic pharmacodynamics. We evaluated the time course of CSF asparagine depletion in children with ALL during and after a course of Escherichia coli asparaginase. PATIENTS AND METHODS: Thirty-one children (24 newly diagnosed and seven at relapse) received E coli asparaginase 10,000 IU/m2 intramuscularly three times weekly for six and nine doses, respectively, as part of multiagent induction chemotherapy. CSF asparagine levels were measured before, during, and after asparaginase dosing. RESULTS: The percentage of patients with undetectable (< 0.04 micromol/L) CSF asparagine was 3.2% (one of 31 patients) at baseline, 73.9% (17 of 23) during asparaginase therapy, and 56.3% (nine of 16) 1 to 5 days, 43.8% (seven of 16) 6 to 10 days, 20.0% (two of 10) 11 to 30 days and 0% (zero of 21) more than 30 days after asparaginase therapy. The proportion of patients with depleted CSF asparagine was higher during asparaginase therapy than at baseline (P < .001), 11 to 30 days (P = .003), and more than 30 days after asparaginase therapy (P < .001). Median CSF asparagine concentrations were 4.42 micromol/L before, less than 0.04 micromol/L during, and less than 0.04 micromol/L at 1 to 5 days, 1.63 micromol/L at 6 to 10 days, 1.70 micromol/L at 11 to 30 days, and 5.70 micromol/L at more than 30 days after asparaginase therapy, respectively. CSF depletion was more common in patients with low baseline CSF asparagine concentrations (P = .003). CONCLUSION: CSF asparagine concentrations are depleted by conventional doses of E coli asparaginase in the majority of patients, but they rebound once asparaginase therapy is completed.  (+info)

Long-term follow-up results of adult patients with acute lymphocytic leukemia or lymphoblastic lymphoma treated with short-term, alternating non-cross-resistant chemotherapy: Japan Clinical Oncology Group Study 8702. Lymphoma Study Group. (2/487)

BACKGROUND: Patients with acute lymphocytic leukemia (ALL) and those with lymphoblastic lymphoma (LBL) have overlapping clinical and immunophenotypic features and they have been treated with the same or very similar chemotherapy regimens. The goal of this multi-institutional phase II trial was to evaluate the therapeutic efficacy of a short-term, six-drug chemotherapy regimen for adult patients with untreated ALL or LBL. METHODS: Forty-six eligible patients, 41 with ALL and five with LBL, were treated with a short-term (planned total therapy duration; 36-38 weeks), simplified chemotherapy program; two courses of VEPA-L (vincristine, cyclophosphamide, prednisolone, doxorubicin, I-asparaginase plus intrathecal methotrexate and prednisolone) followed by four courses of M-VEPA (methotrexate plus VEPA), without the traditional maintenance therapy using daily 6-mercaptopurine and weekly methotrexate. RESULTS: Thirty-six (78%; 95% confidence interval 64-89%) of the 46 eligible patients achieved complete remission (CR). Among the 36 patients who achieved CR, four (11%) died of treatment complications, 26 (72%) relapsed and six (17%) remain alive in continuous CR. The median survival for all 46 eligible patients is 14 months and the median disease-free survival (DFS) for the 36 patients who achieved CR is 11 months. The estimate of the proportion of survival at 7 years of all 46 eligible patients is 15% at a median follow-up time of 96 months and that of DFS of the 36 patients achieving CR is 17% at a median follow-up time of 93 months. Subgroup analysis showed that an elevated serum C-reactive protein (CRP) level, age of 30 years or older, the presence of B-symptom and T-cell phenotype were likely to be associated with shortened survival. Although the observed CR rate (78%) is within the range of satisfaction, the long-term survival rate (15%) is inferior to those of published programs incorporating maintenance therapy. CONCLUSIONS: A fraction of adult patients with ALL or LBL are curable with a short-term, six-drug chemotherapy regimen. However, this simplified therapy of shorter duration cannot be recommended.  (+info)

Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinical study. (3/487)

BACKGROUND AND OBJECTIVE: In a prior study, primary resistant acute lymphoblastic leukemia (RES-ALL) was observed in 11 of 176 (6%) adult patients treated with a four drug regimen (IVAP), its incidence being higher in T-cell or Philadelphia (Ph) chromosome/BCR-ABL rearrangement positive ALL cases with a blast cell count >25x10(9)/L (RES-ALL rate 19%, p=0.04). Aiming to minimize this percentage of resistant disease, fractionated cyclophosphamide (f-CY) was then added to the IVAP regimen. DESIGN AND METHODS: Study 08-96 was a prospective, collaborative phase II trial carried out at eight general hospital centers specialized in the care of hematologic malignancies. Historical IVAP-treated patients served as a retrospective control group. All consecutive, untreated patients (>15 years) with a diagnosis of ALL or advanced-stage lymphoblastic lymphoma (LBL) were eligible. RES-ALL was defined as the persistence of >5% ALL cells in the bone marrow 28-40 days after the start of the IVAP regimen (idarubicin 10 mg/m(2)/d on days 1 and 2; vincristine 2 mg on days 1, 8 and 15; L-asparaginase 6,000 U/m(2) on alternate days 3 6 from day 8; prednisone 60 mg/m(2)/d on days 1-21). In the new study, two f-CY schedules were sequentially adopted: CY 150 or 75 mg/m(2)/bd, given for 4 consecutive days before IVAP (f-CY 1200 or 600, expressing total CY dose in mg/m(2)). RESULTS: Eighty-eight patients were evaluable (age range 15-74 years, blast count 0-240x10(9)/L, 14 T-lineage, 74 B-lineage, 13 Ph/BCR-ABL+). The first 39 patients received the f-CY 1200 schedule, 22 patients received f-CY 600, and the last 27 patients were not given any f-CY. These changes were dictated by the results of interim analyses of the f-CY groups (RES-ALL rate not reduced, myelotoxicity increased). Altogether, compared with the historical IVAP and no f-CY groups, the incidence of RES-ALL was not decreased by the addition of f-CY 1200/600 in B-lineage ALL, regardless of Ph/BCR-ABL expression and blast count. However, none of 14 T-ALL cases in the new study had RES-ALL (8 in f-CY groups, 5 of whom with >25x10(9)/L blast cells), compared to 5/39 (13%, overall) or 4/21 (19%, with >25x10(9)/L blast cells) among the control cases. Owing to small sample size, this difference was not statistically significant. INTERPRETATION AND CONCLUSIONS: This preliminary experience suggests that T-ALL may be more sensitive than B-lineage ALL to an early therapy including f-CY. The hypothesis could be tested in a larger clinical trial.  (+info)

Non-Hodgkin's lymphoma in children: results of treatment with LSA2-L2 protocol. (4/487)

The results obtained with very intensive treatment in previously untreated patients early in the disease are encouraging, and we hope will change the philosophy of most investigators that even in far advanced disease such as those with marrow metastases or multiple primary sites, one can still obtain complete regression at all tumour sites within 1 to 1 1/2 months from onset of therapy by combined treatment with multiple chemotherapeutic agents and radiation therapy to one or more sites.  (+info)

Acute lymphoblastic leukaemia: cyclical chemotherapy with three combinations of four drugs (COAP-POMP-CART regimen). (5/487)

Forty-two adults and children with previously untreated acute lymphoblastic leukaemia (ALL) were entered into a programme of chemotherapy in which three combinations, each of four drugs were administered in a predetermined cyclical rotation together with cranial irradiation and intrathecal injections of methotrexate. Forty-one patients (98%) entered remission and no patient developed neuroleukaemia. Relapse of ALL occurred in 10 patients, and three patients died during remission, while eight patients stopped treatment after two and a half years and have remained in remission for two to 26 months. Comparison of remission and survival experience in this mixed group of children and adults with the experience of children treated at Memphis and in the Medical Research Council's UKALL-I trial showed no significant differences. On the other hand, analysis by prognostic factors showed that neither age nor blast cell count at presentation had any adverse effect in patients treated in this study. No relapses occurred in nine patients with blast cell counts greater than 20 x 109/1 at presentation. This regimen is effective treatment for ALL and may be of special value in patients with poor prognoses. The regiment has not as yet proved superior for the treatment of children with ALL who do not have adverse prognostic features.  (+info)

Applications of synchrotron radiation to protein crystallography: preliminary results. (6/487)

X-ray diffraction photographs of protein single crystals have been obtained using synchrotron radiation produced by an electron-positron storage ring. The diffracted intensities observed with this unconventional source are a factor of at least 60 greater than those obtained with a sealed x-ray tube using the same crystal and instrumental parameters. Diffraction data have been collected by the precession method to higher resolution and using smaller protein crystals than would have been possible with a conventional source. The crystal decay rate in the synchrotron beam for several proteins appears to be substantially less than that observed with Ni-filtered Cu radiation. The tunable nature of the source (which allows selective optimization of anomalous contributions to the scattering factors) and the low angular divergence of the beam make the source very useful for single crystal protein diffraction studies.  (+info)

Hypersensitivity to tobacco antigen. (7/487)

A glycoprotein of molecular weight 18,000 was purified from saline extracts of cured tobacco leaves by ammonium sulfate fractionation, chromatography on Sephadex G-25 and continuous-flow preparative electrophoresis on polyacrylamide gel. Twelve of 31 volunteers (6/15 smokers and 6/16 nonsmokers) exhibited immediate cutaneous hypersensitivity (wheal and flare reactions) when injected intracutaneously with 2 mug of this material. Immunochemically similar material was demonstrated in, and purified from, cigarette smoke condensate and cigarette smoke. The concentration in cigarette smoke condensate ("tar") was determined to be 1.8-3.6 mg/g. Antigenically crossreactive material was also demonstrated in eggplants, green peppers, potatoes, and tomatoes, which, like tobacco, are members of the family Solanaceae.  (+info)

Binding of Clostridium botulinum C2 toxin to asparagine-linked complex and hybrid carbohydrates. (8/487)

Clostridium botulinum C2 toxin is a binary toxin composed of an enzymatic subunit (C2I) capable of ADP-ribosylating actin and a binding subunit (C2II) that is responsible for interaction with receptors on eukaryotic cells. Here we show that binding of C2 toxin depends on the presence of asparagine-linked carbohydrates. A recently identified Chinese hamster ovary cell mutant (Fritz, G., Schroeder, P., and Aktories, K. (1995) Infect. Immun. 63, 2334-2340) was found to be deficient in N-acetylglucosaminyltransferase I. C2 sensitivity of this mutant was restored by transfection of an N-acetylglucosaminyltransferase I cDNA. C2 toxin sensitivity was reduced after inhibition of alpha-mannosidase II. In contrast, Chinese hamster ovary cell mutants deficient in sialylated (Lec2) or galactosylated (Lec8) glycoconjugates showed an increase in toxin sensitivity compared with wild-type cells. Our results show that the GlcNAc residue linked beta-1,2 to the alpha-1,3-mannose of the asparagine-linked core structure is essential for C2II binding to Chinese hamster ovary cells.  (+info)

Abstract: We have studied dose- and time-dependent antitumor and cytotoxic effects of Erwinia carotovora L-asparaginase (ECAR LANS) and Escherichia coli L-asparaginase (MEDAC) on human leukemic cells and human and animal solid tumor cells. We determined the sensitivity of tumor cells to L-asparaginases, as well the effect L-asparaginases on cell growth rate, protein and DNA synthesis per se and with addition of different cytostatics. The data obtained demonstrated that ECAR LANS L-asparaginase suppressed growth of all tested solid tumor cells. Evaluation of leukemic cell number after treatment with L-asparaginases for 24, 48 and 72 h demonstrated that asparagine deficiency did not kill cells but stopped normal cell division and had no effect on protein and DNA synthesis. Cytofluorometric study of solid and leukemic cells demonstrated that the treatment with L-asparaginase for 72 h did not change cell cycle phase distribution and did not increase the number of apoptotic cells. The HL-60 cell line ...
Antibodies against polyethylene glycol (PEG) in healthy subjects raise concerns about the efficacy of pegylated drugs. We evaluated the prevalence of antibodies against PEG among patients with acute lymphoblastic leukemia (ALL) prior to and/or immediately after their first dose of pegylated E.coli asparaginase (PEG-ASNase). Serum samples of 701 children, 673 with primary ALL, 28 with relapsed ALL, and 188 adults with primary ALL were analyzed for anti-PEG IgG and IgM. Measurements in 58 healthy infants served as reference to define cut-points for antibody-positive and -negative samples. Anti-PEG antibodies were detected in ALL patients prior the first PEG-ASNase with a prevalence of 13.9% (anti-PEG IgG) and 29.1% (anti-PEG IgM). After administration of PEG-ASNase the prevalence of anti-PEG antibodies decreased to 4.2% for anti-PEG IgG and to 4.5% for anti-PEG IgM. Pre-existing anti-PEG antibodies did not inhibit PEG-ASNase activity but significantly reduced PEGASNase activity levels in a ...
Asparaginase is one of the key therapeutic agents for childhood acute lymphoblastic leukemia (ALL) [ 1 ]. Asparaginase is an active bacterial enzyme
Growth of Escherichia coli A-l under aerobic conditions in an enriched medium with a total amount of 0.2 per cent glucose was biphasic and asparaginase II activity was detected after depletion of ammonia from the growth medium in the second phase of growth. Glucose was exhausted two hours before ammonia and three hours before asparaginase II activity was detected. The concentration of 3,5-cyclic adenosine monophosphate was found to fluctuate when the dissolved oxygen in the medium reached a low level, when glucose and ammonia were exhausted, and when the cells entered the second stationary phase of growth. Culture tube studies of the growth of E_j_ coli A-l in three per cent nutrient broth with varied concentrations of ammonium chloride and potassium nitrate gave lower specific activity of asparaginase II when this was compared to that seen in three per cent nutrient broth alone. The addition of glucose to the same medium before asparaginase II activity was detected resulted in the production of acid
Hypersensitivity to pegaspargase is associated with inferior survival in pediatric patients with acute lymphoblastic leukemia and lymphoblastic lymphoma. In the past year, drug-supply shortages have led to the lack of an available alternative to pegaspargase. Rather than omit asparaginase from the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma patients with hypersensitivity to pegaspargase, we continued pegaspargase treatments for nine pediatric patients, utilizing a rapid desensitization protocol. There were no adverse events related to the pegaspargase during desensitization, and all patients who were checked had asparaginase serum levels above the threshold of 0.1 IU/mL at 7 to 14 days after pegaspargase therapy.
l -asparaginase (L-ase) is a major drug used to treat acute lymphoblastic leukemia (ALL) [1]. L-ase kills leukemic cells by depleting circulating asparagine pools related to its asparaginase activity [2]. L-ases from Escherichia coli and Erwinia chrysanthemi also degrade l -glutamine due to their glutaminase activity. Th e primary adverse eff ects of L-ase include hypersensitivity, thrombosis, immunosuppression and cytotoxic eff ects. L-ase also induces liver dysfunction with macroand microvesicular steatosis, which may rapidly lead to liver failure, coma and death [3 - 6]. L-ase-induced liver defects are related to decreased protein synthesis due to a reduction in asparagine and glutamine pools [7,8]. Microvesicular steatosis is the most severe form of liver steatosis and is caused by impairment of mitochondrial β -oxidation, leading to the accumulation of unoxidized fatty acids converted to triglycerides [9]. Th is change is often accompanied or dominated by macrovesicular steatosis, as observed with
Asparaginase - Get up-to-date information on Asparaginase side effects, uses, dosage, overdose, pregnancy, alcohol and more. Learn more about Asparaginase
Get information, facts, and pictures about Asparaginase at Encyclopedia.com. Make research projects and school reports about Asparaginase easy with credible articles from our FREE, online encyclopedia and dictionary.
Bacterial asparaginases (amidohydrolases, EC 3.5.1.1) are important enzymes in cancer therapy, especially for Acute Lymphoblastic Leukemia. They are tetrameric enzymes able to catalyze the deamination of L-ASN and, to a variable extent, of L-GLN, on which leukemia cells are dependent for survival. In contrast to other known L-asparaginases, Helicobacter pylori CCUG 17874 type II enzyme (HpASNase) is cooperative and has a low affinity towards L-GLN. In this study, some critical amino acids forming the active site of HpASNase (T16, T95 and E289) have been tackled by rational engineering in the attempt to better define their role in catalysis and to achieve a deeper understanding of the peculiar cooperative behavior of this enzyme. Mutations T16E, T95D and T95H led to a complete loss of enzymatic activity. Mutation E289A dramatically reduced the catalytic activity of the enzyme, but increased its thermostability. Interestingly, E289 belongs to a loop that is very variable in L-asparaginases from the
Angiolillo, A.L., Schore, R.J., Devidas, M., Borowitz, M.J., Carroll, A.J. et al. (2014). Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Childrens Oncology Group Study AALL07P4. Journal of Clinical Oncology, 32(34), 3874-3882.. ...
When you donate blood or platelets at the Kraft Family Blood Donor Center at Dana-Farber Cancer Institute and Brigham and Women's Hospital, or give blood on board the Dana-Farber Cancer Institute/Brigham and Women's Hospital Blood Mobile, you are making a life-saving difference for patients in need - right here in our community.
Comprehensive disease interaction information for asparaginase escherichia coli systemic. Includes Asparaginase - coagulation abnormalities/bleeding.
The antileukemic activity of l-asparaginase (ASNase), an important component of therapy for acute lymphoblastic leukemia, is thought to result from depletion of serum l-asparagine (Asn). In studies of the pharmacological effects of ASNase, investigators have reported prolonged reduction in the serum concentration of Asn after the administration of ASNase. Such measurements may not be valid because ASNase present in the blood sample may hydrolyze Asn before its determination. We examined recovery of [U-14C]Asn from blood samples with and without various concentrations of added ASNase. In the presence of ≥0.01 IU/ml of ASNase, the amount of [U-14C]Asn recovered was ,15% of that without ASNase. Utilizing this assay, we studied the effect of 2 known inhibitors of ASNase in an attempt to improve Asn recovery. In the presence of aspartic β semialdehyde (ASA), or 5-diazo-4-oxo-l-norvaline (DONV), and up to 1.0 IU/ml ASNase, Asn levels remained at ,90% of control. ASA prevented the hydrolysis of ...
Dana-Farber employs more than 4,274 full-time and part-time people, 467 faculty, and has annual gross revenues of about $1,086,638,000.[1] There are more than 299,202 adult and pediatric patient visits a year, and it is involved in more than 700 clinical trials. It is internationally known for its research and clinical excellence. Expertscape ranks its programs in aplastic anemia[2] and multiple myeloma[3] as best in the world. It has been also ranked the fourth best cancer hospital in the United States by U.S. News & World Report.[4] Dana-Farber is a member of the Multiple Myeloma Research Consortium. In addition to being a principal teaching affiliate of Harvard Medical School, Dana-Farber is also a federally designated Center for AIDS Research, and a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC),[5] a federally designated Comprehensive Cancer Center. Providing advanced training in cancer treatment and research for an international faculty, Dana-Farber conducts ...
The present protocol will compare the biologic effects of PEG-asparaginase vs native-forms of asparaginase in a randomized trial using the same dosages and schedules used in the POG 9411 study. Comprehensive studies, including the measurement of antibodies and asparagine levels as well as the pharmacokinetics of L-asparaginase, will be performed. This protocol will also study the changes in topoisomerase I and topoisomerase II levels and the fractions of topoisomerase I/II translocations in malignant lymphoblasts after upfront window topotecan therapy, and correlate oncolytic response with these changes. Secondary objectives include: - To compare changes in asparagine levels 28 days after initiation of treatment with asparaginase between the two groups. - To estimate the pharmacokinetics of L-asparaginase, compare the pharmacokinetics between the two groups of patients, and correlate the pharmacokinetics with the development of antibody to asparaginase and depletion of asparagine. - To measure ...
BOSTONThe Dana-Farber Cancer Institute and the National Foundation for...With eight other NFCR research centers at universities and research ho...How the Center Works...Traditionally monoclonal antibodies have been derived from mouse mode...,Dana-Farber,launches,NFCR,Center,for,Therapeutic,Antibody,Research,and,Engineering,biological,biology news articles,biology news today,latest biology news,current biology news,biology newsletters
2017 PCF Challenge Award ($1 Million) Principal Investigators: Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Mary-Ellen Taplin, MD (Harvard: Dana-Farber Cancer Institute) Co-Investigators: Wassim Abida, MD, PhD (Memorial Sloan Kettering Cancer Center), Anuradha Gopalan, MD (Memorial Sloan Kettering Cancer Center), Glenn Heller, PhD (Memorial Sloan Kettering Cancer Center), Maika Mitchell, PhD (Memorial Sloan Kettering Cancer Center), Nikolaus Schultz, PhD (Memorial Sloan Kettering Cancer Center), Steven Balk, MD, PhD (Harvard: Beth Israel Deaconess Medical Center), Atish Choudhury, MD, PhD (Harvard: Dana-Farber Cancer Institute), Eliezer Van Allen, MD (Harvard: Dana-Farber Cancer Institute), Adam Kibel, MD (Harvard: Brigham and Womens Hospital), Huihui Ye, MD, MSc (Harvard: Beth Israel Deaconess Medical Center), Rosina Lis, MD (Harvard: Dana-Farber Cancer Institute), Wai Yi Tsui, MD, PhD (Memorial Sloan Kettering Cancer Center), Michaela Bowden, PhD (Harvard: Dana-Farber Cancer ...
l-Asparaginase is a key therapeutic agent for treatment of childhood acute lymphoblastic leukemia (ALL). There is wide individual variation in pharmacokinetics, and little is known about its metabolism. The mechanisms of therapeutic failure with l-asparaginase remain speculative. Here, we now report that 2 lysosomal cysteine proteases present in lymphoblasts are able to degrade l-asparaginase. Cathepsin B (CTSB), which is produced constitutively by normal and leukemic cells, degraded asparaginase produced by Escherichia coli (ASNase) and Erwinia chrysanthemi. Asparaginyl endopeptidase (AEP), which is overexpressed predominantly in high-risk subsets of ALL, specifically degraded ASNase. AEP thereby destroys ASNase activity and may also potentiate antigen processing, leading to allergic reactions. Using AEP-mediated cleavage sequences, we modeled the effects of the protease on ASNase and created a number of recombinant ASNase products. The N24 residue on the flexible active loop was identified as ...
Extranodal NKT cell lymphoma Image NCI. Extranodal natural killerT-cell lymphoma nasal type ENKTL has a long-winded title but is an aggressive form of cancer that is difficult to treat successfully. It tends to affect people in Latin America and Asia rather then the West but is becoming more prevalent in the US. Although it has been described as...
Gordon J. Freeman, PhD Find a cancer doctor with Dana Farbers physician directory. Read how to search for a cancer doctor by name for breast cancer, cervical cancer, ovarian cancer, lung cancer, stomach cancer, testicular cancer, prostate cancer, sarcoma, lymphoma, leukemia, brain tumor, melanoma, bladder cancer, blood disorders, skin cancer, colon cancer, and more at Dana-Farber Cancer Institute.
Dana-Farber Cancer Institute is a top cancer center where leading mesothelioma doctors use the latest mesothelioma treatment protocols to help their cancer patients.
Health,Dana-Farber Cancer Institute scientists have developed a test that is ...The researchers demonstrated that chronic lymphocytic leukemia CL...The research in the laboratory of Anthony Letai MD PhD of Dana-...Letai was a colleague of the late Stanley J. Korsmeyer MD of Dan...Inspired by this pioneering research drug companies have begun te...,New,Test,Predicts,CLLs,Sensitivity,to,Experimental,Drug,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
A variety of efforts are underway to apply gene therapy to cancer treatment. Most are in early, exploratory stages, where theyre being studied in the laboratory or in clinical research trials. One approach, however, known as CAR T-cell therapy, has received approval from the U.S. Food and Drug Administration for use as a therapy in certain groups of patients and is expected to receive additional approvals in the near future.. Research in gene therapy for cancer is currently focused in multiple areas, including genetically engineered viruses that directly kill cancer cells, gene transfer to alter the abnormal functioning of cancer cells, and immunotherapy (which includes CAR T-cell therapy), which helps the immune system better find and kill tumor cells.. Learn more about immunotherapy from the Center for Immuno-Oncology at Dana-Farber Cancer Institute.. Genetically Engineered Viruses. This approach uses specially modified viruses (called oncolytic viruses) that target and destroy cancer cells ...
2017 PCF Challenge Award ($1 Million) Award Donor: Janssen Pharmaceuticals Principal Investigators: Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Mary-Ellen Taplin, MD (Harvard: Dana-Farber Cancer Institute) Co-Investigators: Wassim Abida, MD, PhD (Memorial Sloan Kettering Cancer Center), Anuradha Gopalan, MD (Memorial Sloan Kettering Cancer Center), Glenn Heller, PhD (Memorial Sloan Kettering Cancer Center), Maika Mitchell, PhD (Memorial Sloan Kettering Cancer Center), Nikolaus Schultz, PhD (Memorial Sloan Kettering Cancer Center), Steven Balk, MD, PhD (Harvard: Beth Israel Deaconess Medical Center), Atish Choudhury, MD, PhD (Harvard: Dana-Farber Cancer Institute), Eliezer Van Allen, MD (Harvard: Dana-Farber Cancer Institute), Adam Kibel, MD (Harvard: Brigham and Womens Hospital), Huihui Ye, MD, MSc (Harvard: Beth Israel Deaconess Medical Center), Rosina Lis, MD (Harvard: Dana-Farber Cancer Institute), Wai Yi Tsui, MD, PhD (Memorial Sloan Kettering Cancer Center), Michaela Bowden, ...
20% of children with ALL still fails to be cured. The ALL-2008 protocol is a treatment and research protocol that aims to improve the overall outcome of Nordic children and adolescents with ALL in comparison with the ALL-2000 protocol and previous NOPHO protocols.. The specific and primary objectives of the randomised study is:. To test if intramuscular PEG-asparaginase administered either at six or two week intervals from day 92 until 8 months from diagnosis for patients with non-HR ALL will result in equal probability of EFS. As secondary endpoints asparaginase antibody production and toxicity including allergic reactions in the treatment-arms will be analysed ...
Although dyslipidemia has been reported during ALL therapy, there have been few systematic studies, and no prior study with dex pharmacokinetics (PK) or asparaginase biomarkers. We studied serum high density lipoprotein (HDL), low density lipoprotein (LDL), triglycerides, and cholesterol in 313 pediatric ALL patients enrolled on St. Jude Total XV at baseline (day 15 consolidation), and weeks (wks) 7, 8 and 12 of continuation therapy. Patients on the standard/high risk (SHR) arm (n=163) were exposed to more asparaginase (wks 1-12) than those on the low risk (LR) arm (n=150, wks 7-9) as reflected by lower serum albumin at wks 7, 8, and 12 (p ,10-6, all time points). Dex was given during wks 1, 4, 7, and 9. Dex PK was assessed at the start and end of wk 7.. LDL decreased after asparaginase (wk 8 in the LR and wk 7 in the SHR arm). HDL decreased from wk 7 to 8, after one wk of dex and asparaginase. Cholesterol increased during therapy. The largest effect of therapy was on triglycerides, which ...
V.3.1 - Rechutes neuro-méningées : extrait du FRALL 90 4 cures à 2 semaines dintervalle sont prévues Methotrexate 8g/m² dose totale scindée en 2g/m² IV en 1 h puis 6g/m² en 23 h Cyclophosphamide 600 mg/m² à débuter dès la fin du metho Rescue acide folinique 4 après la fin du metho PL triple (Cytarabine 40 mg, Methotrexate 15 mg, Depomedrol 40 mg ) 3 fois par semaine jusquà stérilisation du LCR Vincristine 2 mg IVL J1 Methotrexate 80 mg/m² J1 Asparaginase 40 000 UI IV J2 Vincristine 2 mg IVL J8 Methotrexate 120 mg/m² J8 Asparaginase 40 000 UI IV J9 Vincristine 2 mg IVL J15 Methotrexate 160 mg/m² J15 Asparaginase 40 000 UI IV J16 Vincristine 2 mg IVL J22 Methotrexate 200 mg/m² J22 Asparaginase 40 000 UI IV J23 Cyclophosphamide 300 mg/m² IV toutes les 12 h J1 J2 J3 Doxorubicine 50 mg/m² IV J4 Vincristine 2 mg IVL J4 Dexamethasone 40 mg IV J1 à J4 Methotrexate 200 mg/m² en 2 h (IV bolus) puis 800 mg/m² en 22 h IVC à J1 Rescue acide folinique Cytarabine 3 g/m² toutes les ...
Brand Names Elspar Kidrolase (There may be other brand names for this medication) How is Asparaginase Administered? Your medicine may be given by given intravenously (IV), which means it will be given through a tube placed in a vein, usually in your arm, wrist, hand or chest. You may also receive the drug through a shot in a large muscle in your buttock, upper arm or thigh. (IM injection) What is it Used For? This drug is used to treat certain kinds of leukemia and other cancers.
Search for Asparaginase (5000IU) Manufacturers / Generic Brands / Substitute / alternatives, prices, m.r.p. Order Medicines online on PillsBills.com. Free shipping all over India.
Asparaginase is an important drug i the treatment of childhood leukaemia.. The aim of this project is to study the pharmacokinetics, pharmacodynamics and antibody development and hypersensitivity reactions during prolonged PEG-asparaginase treatment.. Study part 1) Asparaginase pharmacokinetics and pharmacodynamics during prolonged PEG-asparaginase treatment: A NOPHO ALL-2008 study. Study part 2) Asparagine depletion in cerebrospinal fluid: A NOPHO ALL-2008 study. Study part 3) A characterization of PEG-asparaginase hypersensitivity in children treated according to the NOPHO ALL 2008 protocol. Perspectives: New knowledge about PEG-asparaginase treatment regarding dosing, dosing interval, adverse effects and EFS, which may lead to improved future therapy. Patients: Children diagnosed with acute lymphoblastic leukaemia in the Nordic Countries ...
Asparaginase is a critical agent in the treatment of ALL. This enzyme deaminates asparagine, interfering with protein synthesis and resulting in cell death as lymphoblasts are deficient in asparagine synthetase. Eryaspase is a dispersion of homologous red blood cells (RBCs) encapsulating L-asparaginase formulated in a preservative solution for infusion. The formulation of eryaspase has evolved during its development. Two sources of L-asparaginase (drug substance) from Medac GmbH can be used as raw material and encapsulated in the RBCs: native (Kidrolase®) or recombinant L-asparaginase (Spectrila®). This study is designed to investigate the PK comparability of both eryaspase formulations: native or recombinant asparaginase as the starting material, when administered as monotherapy and in combination with chemotherapy during induction and consolidation phases for the treatment of children and young adults presenting with ALL/LBL. ...
Asparaginase Erwinia chrysanthemi - Get up-to-date information on Asparaginase Erwinia chrysanthemi side effects, uses, dosage, overdose, pregnancy, alcohol and more. Learn more about Asparaginase Erwinia chrysanthemi
The dose- and time-dependent antitumor and cytotoxic effects of L-asparaginases from Erwinia carotovora (ECAR LANS) and Escherichia coli (MEDAC) have been investigated using human leukemic cells and human and animal solid tumor cells. These included human T-cell acute lymphoblastic leukemia cell lines (Jurkat, Jurkat/A4, Molt-4), human chronic myeloid leukemia K562 cells, human promyelocytic leukemia HL-60, and also human solid tumor cells (prostate carcinoma LnCap, breast adenocarcinoma MCF7, ovarian adenocarcinoma SCOV-3 and carcinoma CaOV, hepatocarcinoma Hep G2, fibrosarcoma HT-1080) and animal solid tumor cells (rat Gassers ganglion neurinoma cells GGNC-1, mouse glioblastoma EPNT-5). We investigated sensitivity of tumor cells (seeded at different density) to L-asparaginases, as well the effect of L-asparaginases on cell growth rate, protein and DNA synthesis in the presence of various cytostatics. Cell cycle analysis by flow cytofluorimetry and detection of apoptotic cells before and after ...
Looking for online definition of central nervous system prophylaxis in the Medical Dictionary? central nervous system prophylaxis explanation free. What is central nervous system prophylaxis? Meaning of central nervous system prophylaxis medical term. What does central nervous system prophylaxis mean?
Looking for online definition of ansa subclavia in the Medical Dictionary? ansa subclavia explanation free. What is ansa subclavia? Meaning of ansa subclavia medical term. What does ansa subclavia mean?
Background: Hyperglycaemia is a common side effect of steroid and L-asparaginase combinations, occurring mostoften during acute lymphoblastic leukemia (ALL) induction phase. To date in Indonesia, it has not been obtained dataon the incidence of hyperglycemia in children with ALL in the induction phase and how the role of combinations ofL-asparaginase and different type of steroid used. The purpose of this study is to determine the incidence of hyperglycemiain children ALL induction phase, knowing the difference between prednisone and dexamethasone (in combination withL-asparaginase) in causing hyperglycemia in children with ALL and determine the relationship of other factors relatedto hyperglycaemia. Methods: This was a prospective analytic study with a pre- and post-test design, conducted inthree hospitals (Cipto Mangunkusumo Hospital, Dharmais Cancer Hospital, and Gatot Soebroto Hospital). Patientsblood glucose levels were checked at the 3rd (pretest), 4th, 5th and 6th week of protocol (post-test).
Asparaginase (Erwinia chrysanthemi) reference guide for safe and effective use from the American Society of Health-System Pharmacists (AHFS DI).
ORIGINAL ARTICLES Minerva Pediatrica 2000 April;52(4):205-14. Seizures during treatment for acute lymphoblastic leukemia in children. Mainero G., Barisone E., Boffi P., Farinasso L., Landolfi C., Dalponte S., Sicca E., Papalia F., Miniero R., Madon E.. Abstract PDF. REVIEWS Minerva Pediatrica 2000 April;52(4):215-26. Food hypersensitivity in early infancy: immunopathogenesis and clinical disorders. Vigi V., Fanaro S.. Abstract PDF. CASE REPORT Minerva Pediatrica 2000 April;52(4):227-30. Floating-Harbor syndrome: first case in Italy. Evidence of growth hormone deficiency. Femiano P., Castaldo V., Scarano G.. Abstract PDF. CASE REPORT Minerva Pediatrica 2000 April;52(4):231-4. Abdominal pain in children: a case of acalculous cholecystitis. Trada M., Garzoli E., Falzoni P. U., De Franco S., Sacco F., Aguzzi A., Bona G.. Abstract PDF. CASE REPORT Minerva Pediatrica 2000 April;52(4):235-42. Clinical radiologic and RM long term follow-up study in a thalassaemic patient with osteocondrodystrophic ...
ORIGINAL ARTICLES Minerva Pediatrica 2001 April;53(2):87-94. Cardiac involvement in Kawasaki disease. Our experience. Sciacca P., Falsaperla R., Barone P., Tornambene G., Mattia C., Marletta M., Betta P., Distefano G.. Abstract PDF. ORIGINAL ARTICLES Minerva Pediatrica 2001 April;53(2):95-8. Multicystic dysplastic kidney and contralateral vesicoureteral reflux. Renal growth. Fanos V., Sinaguglia G., Vino L., Pizzini C., Portuese A.. Abstract PDF. REVIEWS Minerva Pediatrica 2001 April;53(2):99-106. Respiratory tract infections caused by respiratory syncytial virus in children. Diagnosis and treatment. Van Woensel J. B. M., Kimpen J. L. L., Brand P. L. P.. Abstract PDF. REVIEWS Minerva Pediatrica 2001 April;53(2):107-20. Assessment and measurement of pain in infants and children. Trapanotto M., Benini F., Agosto C., Pardi C., Lazzarin P., Zacchello F.. Abstract PDF. SPECIAL ARTICLES Minerva Pediatrica 2001 April;53(2):121-8. Experience of comic relief in pediatric hospital. Bruschettini P., ...
Targeting amino acid metabolism has therapeutic implications for aggressive brain tumors. Asparagine is an amino acid that is synthesized by normal cells. However, some cancer cells lack asparagine synthetase (ASNS), the key enzyme for asparagine synthesis. Asparaginase (ASNase) contributes to eradication of acute leukemia by decreasing asparagine levels in serum and cerebrospinal fluid. However, leukemic cells may become ASNase-resistant by up-regulating ASNS. High expression of ASNS has also been associated with biological aggressiveness of other cancers, including gliomas. Here, the impact of enzymatic depletion of asparagine on proliferation of brain tumor cells was determined. ASNase was used as monotherapy or in combination with conventional chemotherapeutic agents. Viability assays for ASNase-treated cells demonstrated significant growth reduction in multiple cell lines. This effect was reversed by glutamine in a dose-dependent manner -- as expected, because glutamine is the main amino ...
We found that the mechanism by which perphenazine was killing cancer cells was independent of its antipsychotic activity, says Gutierrez, who was a fellow in Looks laboratory and who has recently established his own lab at Dana-Farber/Boston Childrens. When we looked more closely, we found that the drug also activated a tumor-suppressing protein called PP2A.. This is unusual. In general, anticancer drug research seeks to find proteins that are active only in cancer cells and develop ways to shut them off. But perphenazine was doing the opposite: In reactivating PP2A, the drug was reactivating a protein that the tumor cells had turned off, triggering the cells to die.. In other words, perphenazine was relieving the suppression on the suppressor, thereby forcing cancer cells in the model to die.. We rarely find potential drug molecules that activate an enzyme, Gutierrez explains. But, here, perphenazine is restoring the activity of PP2A in the T-ALL cell.. Perphenazine was relieving the ...
PNEI REVIEW - Oncologia integrata in radioterapia: evidenze scientifiche e gestione degli effetti collaterali ( Il successo della radioterapia nelleradicare il tumore dipende dalla dose totale erogata, ma la tolleranza dei tessuti sani circostanti il tumore ne limita la dose. Le manifestazioni cliniche acute e tardive possono essere molto gravi. Di recente le medicine complementari e integrative hanno attratto linteresse dei ricercatori e dei medici poiché sono stati pubblicati articoli circa alcuni benefi ci apportati dal trattamento con fi toterapici e agopuntura per sintomi quali cancer-related fatigue, nausea e vomito, diarrea, dolore oncologico, radiodermite, mucosite, ansia e depressione. Cè un buon livello di evidenza circa il ruolo dellattività fi sica/sport e della nutrizione in oncologia, dove si raccomanda una dieta regolare a base di vegetali. Lattività fi sica si raccomanda anche durante la chemio/radioterapia per la riduzione degli effetti collaterali del trattamento. La modifi
The ansa cervicalis, also called ansa hipoglossi, is a U-shaped, curved stretch of nerve, which is part of the cervical plexus. It is formed by myelinated nerve fibers coming from spinal roots C1, C2, and C3. From the loop of the ansa cervicalis, three nerves projects downward to innervate the sternothyroid, the sternohyoid, and the omohyoid muscles. ...
Exocytotic secretion of digestive enzymes from pancreatic acinar cells is elicited by physiological cytosolic Ca2+ signals, occurring as repetitive short-lasting spikes largely confined to the secretory granule region, that stimulate mitochondrial adenosine triphosphate (ATP) production. By contrast, sustained global cytosolic Ca2+ elevations decrease ATP levels and cause necrosis, leading to the disease acute pancreatitis (AP). Toxic Ca2+ signals can be evoked by products of alcohol and fatty acids as well as bile acids. Here, we have investigated the mechanism by which l-asparaginase evokes AP. Asparaginase is an essential element in the successful treatment of acute lymphoblastic leukaemia, the most common type of cancer affecting children, but AP is a side-effect occurring in about 5-10% of cases. Like other pancreatitis-inducing agents, asparaginase evoked intracellular Ca2+ release followed by Ca2+ entry and also substantially reduced Ca2+ extrusion because of decreased intracellular ATP ...
David M. Jackman, MD from Dana-Farber Cancer Institute recently answered your questions on lung cancer as part of CancerConnects Guest Moderator Ask the Expert series. Dr. Jackman is a thoracic oncologist in the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute.. Question: My sister has stage 3 lung cancer and presented with anemia, nausea and weight loss. They didnt want to treat her until they figured out what was going on with the nausea so we waited for 2 months while they did tests. Now they are finally moving, but still dont know why she is anemic and can barely eat. We meet with the radiation oncologist Friday and want to know what to ask. Is there a specific kind of treatment modality we should be asking about? Tomotherapy, cyberknife, proton therapy? I just dont know enough about it. We are near enough to Chicago that we have everything available, just want to make sure our physician offers the best option.. Dr. Jackmans Response: When we think about Stage III lung ...
Scientists may have found a new tool for studying-and maybe even treating-Type 2 diabetes.. A team of scientists from the Florida campus of The Scripps Research Institute (TSRI), Dana-Farber Cancer Institute, Harvard Medical School and the Yale University School of Medicine have identified a new class of compounds that reduce production of glucose in the liver. One of these compounds, designed and optimized by TSRI scientists, significantly improves the health of diabetic animal models by reducing glucose levels in the blood, increasing insulin sensitivity, and improving glucose balance.. The study, published recently in the journal Cell, was led by Pere Puigsever of Harvard Medical School and the Dana-Farber Cancer Institute.. The compound they identified, called SR-18292, modifies a protein known as PGC-1α. This protein plays a pivotal role in energy balance and helps control genes involved in energy metabolism. When cells overexpress PGC-1, during fasting or starvation, for example, glucose ...
TY - JOUR. T1 - Quality of life during active treatment for pediatric acute lymphoblastic leukemia. AU - Sung, Lillian. AU - Yanofsky, Rochelle. AU - Klaassen, Robert J.. AU - Dix, David. AU - Pritchard, Sheila. AU - Winick, Naomi. AU - Alexander, Sarah. AU - Klassen, Anne. PY - 2011/3/1. Y1 - 2011/3/1. N2 - The objectives of the study were to describe quality of life (QoL), identify predictors of worse QoL and examine QoL during different phases of active therapy for acute lymphoblastic leukemia (ALL). A multiinstitutional cross-sectional study was performed in children with ALL. We included children at least 2 months from diagnosis who were receiving treatment in first remission. Parents described QoL using the PedsQL 4.0 Generic Core Scales and the PedsQL 3.0 Acute Cancer Module. The 206 children on treatment for ALL had overall [median 62.5, 95% confidence interval (CI) 34.8-94.4], physical (median 62.5, 95% CI 18.8-100.0) and psychosocial (median 65.4, 95% CI 38.3-94.2) summary scores that ...
CMC_Design/childrens/departments/Cancer and Blood Disorders CCBD,/CMC_Design/childrens/departments/Nephrology,/CMC_Design/childrens/departments/Psychiatry and Psychology,/CMC_Design/childrens/departments/Radiology X ray,/CMC_Design/childrens/departments/Transplant,/CMC_Design/childrens/departments/Cardiology and Cardiothoracic Surgery Heart Center,/CMC_Design/childrens/departments/Anesthesiology,/CMC_Design/childrens/departments/Cerebrovascular Disorders CCDC,/CMC_Design/childrens/departments/Neurosurgery,/CMC_Design/childrens/departments/Neonatal-Perinatal Medicine,/CMC_Design/childrens/departments/1_Program/Fetal Evaluation and Treatment Alliance Program FETAL,/CMC_Design/childrens/departments/1_Program/NICU Program,/CMC_Design/childrens/departments/1_Program/Cancer Susceptibility,/CMC_Design/childrens/departments/1_Program/Hematology,/CMC_Design/childrens/departments/1_Program/Oncology,/CMC_Design/childrens/departments/1_Program/Mood Disorders General ...
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved the intravenous...
Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it has resubmitted to the European Medicine Agency (EMA) its Marketing Authorization Application (MAA) for eryaspase (GRASPA®) for the treatment of patients with relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL). The MAA resubmission includes the data from ERYTECHs GRASPALL 2009-06 Phase 2/3 clinical trial in children and adults with R/R ALL as well as additional data to address the outstanding questions of the Committee for Medicinal Products for Human Use (CHMP) of the EMA. The GRASPALL Phase 2/3 trial, showed positive efficacy and safety results with GRASPA in combination with chemotherapy as compared to native L-asparaginase in patients with R/R ALL. The patients treated with GRASPA experienced a mean duration of L-asparaginase activity that was al
Reconstitute powder with 4 mL SWI or NS to a final concentration of 2,500 IU/mL. For IM injection, Trissel recommends reconstitution with 2 mL NS to give a final concentration of 5,000 IU/mL. For IM injections of high dose therapy (10,000 IU), the 10,000 IU vial can be reconstituted with 0.5 mL of NS to give a final concentration of 20,000 IU/mL. If ,2mL solution is need, prepare in 2 syringes for injection into 2 different sites. To avoid foaming, rotate gently; do not shake ...
To date, case-control studies on the association between methylenetetrahydrofolate reductase (MTHFR) C677T and childhood acute lymphoblastic leukemia have provided either controversial or inconclusive results. To clarify the effect of MTHFR C677T on the risk of childhood acute lymphoblastic leukemia …
In this article (Clin Cancer Res 2013;19:5240-9), which was published in the September 15, 2013, issue of Clinical Cancer Research (1), a listing of the Grant Support was mistakenly included in the Acknowledgments section. The correct Grant Support listing should read as follows: This study was supported by the Canadian Institutes of Health Research, Leukemia Lymphoma Society of Canada, Charles Bruneau Foundation, and Centre dexcellence en Oncologie pédiatrique et en soins palliatifs. Dana-Farber Cancer Institute ALL treatment protocols are supported by the National Cancer Institute/NIH grant 5 P01CA068484. The authors regret this error. ...
Relevant drugs/supplements/protocols for brain cancer: cusp9 protocol (Ref.) Chlorimipramine, the keto diet and Boswellic Acid Noscapine inhibits tumor growth in TMZ-resistant gliomas http://www.ncbi.nlm.nih.gov/pubmed/21925789 Autophagy inhibition improves the efficacy of curcumin/temozolomide combination therapy in glioblastomas http://www.ncbi.nlm.nih.gov/pubmed/25542083 Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy http://www.ncbi.nlm.nih.gov/pubmed/25434381 Tetanus Vaccine Boosts Cancer Therapy http://www.nbcnews.com/health/cancer/tetanus-vaccine-boosts-cancer-therapy-n321596 Asparagine depletion ...
Charles S. Fuchs, MD, MPH, was appointed the Director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital on January 1, 2017. Prior to joining Yale, Dr. Fuchs was the Director of the Gastrointestinal Cancer Center at Dana-Farber Cancer Institute, Professor of Medicine at Harvard Medical School and the Robert T. and Judith B. Hale Chair in Pancreatic Cancer. He led the Dana-Farber/Harvard Cancer Center Gastrointestinal Malignancies Program and the DF/HCC SPORE Grant in Gastrointestinal Cancers. In addition to his leadership responsibilities, Dr. Fuchs splits his time between laboratory-based research, clinical research, and clinical patient care. His laboratory focuses on biochemical markers of GI cancer risk, molecular predictors of patient prognosis in colorectal and pancreatic cancers, and the discovery of novel targets for therapy. Dr. Fuchs is a member of the Scientific Advisory Board for the Lustgarten Foundation for Pancreatic Cancer and a cadre member of GI Committee ...
This is an extraordinary result, said George Demetri, MD, professor of medicine at Harvard Medical School, director of the Ludwig Center at Dana-Farber/Harvard Cancer Center, and director of the Center for Sarcoma and Bone Oncology at Dana-Farber Cancer Institute, in a Forbes interview. Lots of doctors dont realize theres a possibility that their patients might have this genetic change. They dont screen for TRK mutations, so 9 in 10 cancer patients who might benefit from this drug likely dont have the opportunity to try it.. Progress with larotrectinib is along the lines of Demetris prediction in a post to forecast cancer therapy advances in 2017. In an interview for that post, he said it is good news that we are still uncovering virtually monogenic diseases-diseases that are driven by single oncogenic fusions or mutations, referring to NTRK fusions. Therapies targeting single mutations, such as NTRK fusions, lead to durable and dramatic responses, added Demetri, who is a board member ...
Dr. Laurie H. Glimcher is the President and CEO of the Dana-Farber Cancer Institute, Principal Investigator and Director of the Dana-Farber/Harvard Cancer Center, and the Richard and Susan Smith Professor of Medicine at Harvard Medical School. Previously, she was the Stephen and Suzanne Weiss Dean and Professor of Medicine of Weill Cornell Medicine and Provost for Medical Affairs of Cornell University. From 1991 to 2012 she served as the Irene Heinz Given Professor of Immunology at the Harvard School of Public Health and Professor of Medicine at Harvard Medical School serving as Senior Physician and Rheumatologist at Brigham and Womans Hospital. Dr. Glimcher is a distinguished immunologist, widely renowned for her work in one of the most promising areas of cancer research.. Dr. Glimcher is a Member of the National Academy of Sciences, a Fellow of the American Academy of Arts and Sciences, a Member of the National Academy of Medicine, and the former President of the American Association of ...
Some 42 migrants are continuing a protest that has been underway for several days in front of the main church on the island of Lampedusa. © ANSA
Acute pancreatitis (AP), a human disease in which the pancreas digests itself, has substantial mortality with no specific therapy. The major causes of AP are alcohol abuse and gallstone complications, but it also occurs as an important side effect of the standard asparaginase-based therapy for childhood acute lymphoblastic leukemia. Previous investigations into the mechanisms underlying pancreatic acinar cell death induced by alcohol metabolites, bile acids, or asparaginase indicated that loss of intracellular ATP generation is an important factor. We now report that, in isolated mouse pancreatic acinar cells or cell clusters, removal of extracellular glucose had little effect on this ATP loss, suggesting that glucose metabolism was severely inhibited under these conditions. Surprisingly, we show that replacing glucose with galactose prevented or markedly reduced the loss of ATP and any subsequent necrosis. Addition of pyruvate had a similar protective effect. We also studied the effect of ...
US scientists have identified a way in which cancer cells can become resistant to the cancer drug cetuximab (Erbitux), and suggest that treatments that are already available might be able to overcome this resistance.. Researchers from the Dana-Farber Cancer Institute in Boston, US, have been studying why some patients only experience short-term benefits with cetuximab, or none at all.. Cetuximab is an antibody that interferes with cancer cell growth. It can be given in combination with chemotherapy to patients with bowel cancer or head and neck cancer.. Until now, scientists didnt know why some cancers failed to respond to the drug, or initially responded but then became resistant.. The new study, published in Science Translational Medicine, found that in some of the drug-resistant cells, a protein known as ErbB2 (also known as HER2/neu) was sending grow signals.. These were bypassing the stop growing signals caused by the drug.. Pasi Janne, the studys co-senior author, said: ErbB2 ...
4:00 KEYNOTE PRESENTATION: TMB/GEP Dual Biomarker Strategy for Personalized Checkpoint Blockade Combination Immunotherapy. Jianda Yuan, MD, PhD, Senior Director, Translational Oncology, Merck. Immune checkpoint blockade therapies are revolutionizing the standard cancer treatment. Despite the current success of these therapies, not all patients respond to immunotherapy. Combination approaches are the keys to improving clinical response. Tumor mutational burden (TMB) and gene expression profile (GEP) are emerging biomarkers predicting patient response. Dual TMB/GEP biomarkers allow us to understand novel translational biomarkers to stratify patients effectively for personalized cancer immunotherapy.. 4:30 Is There a Role for Biomarkers in this Era of Combination Immunotherapy?. Kathleen M. Mahoney, MD, PhD, Clinical Instructor, Beth Israel Deaconess Medical Center; Research Fellow, Dana-Farber Cancer Institute. Combinations with PD-1 immune checkpoints such as chemotherapy, ipilimumab or VEGF ...
PHILADELPHIA - An increasing body mass index was associated with a higher risk for colorectal cancer with a specific molecular characteristic, and inversely, physical activity was linked to a decreased risk for that same cancer, according to data published in Cancer Research, a journal of the American Association for Cancer Research.. We know that exercise and avoiding obesity decrease colorectal cancer risk, but little is known about why, said Shuji Ogino, M.D., Ph.D., associate professor of pathology at Dana-Farber Cancer Institute and associate professor in the Department of Epidemiology at Harvard School of Public Health in Boston, Mass. In this study, we used a biomarker named CTNNB1, which is a molecule implicated in cancer and obesity, to divide patients into two groups, CTNNB1-positive and CTNNB1-negative.. Ogino and colleagues used data from more than 100,000 women from the Nurses Health Study and more than 45,000 men in the Health Professionals Study to examine whether there was ...
New Clinical Trials in Prostate Cancer. William K. Oh, M.D. Clinical Director, Lank Center for Genitourinary Oncology Dana-Farber Cancer Institute Associate Professor, Harvard Medical School. U.S. Cancer Statistics: Prostate Cancer 2007. Leading cause of cancer in men (218,890 cases, 29%) Slideshow 63801 by RexAlvis
Scientists who studied a highly cancer-prone single family have identified a rare, inherited gene mutation that may raise the lifetime risk of pancreatic and other cancers. Their findings were published by Nissim et al in Nature Genetics.. The discovery of the previously unknown mutation could lead to routine testing of individuals with a strong family history of pancreatic cancer to determine if they carry a mutation occurring in the gene RABL3. If so, they could be screened to detect pancreatic cancer in an earlier, potentially more treatable stage. In addition, their relatives could choose to be tested to learn if they carry the mutation.. There is evidence that catching pancreatic cancer through screening of high-risk individuals may improve outcomes, said first study author Sahar Nissim, MD, PhD, a cancer geneticist and gastroenterologist at Dana-Farber Cancer Institute and Brigham and Womens Hospital. About 10% of pancreatic cancers have a familial pattern, and in most cases, the ...
Jonathan D. Schoenfeld, MD, MPhil, MPH, director, melanoma radiation oncology, physician, assistant professor of radiation oncology, Harvard Medical School, Dana-Farber Cancer Institute, discusses potential combination regimens of low-dose radiation therapy and immunotherapy to treat patients with head and neck cancer.
The ASCO Post asked several myeloma experts their views on the investigational agents that could make Dr. Andersons prediction a reality. Their thoughts on antibody-based treatments follow. (See page 21 for their perspectives on the new proteasome inhibitors in multiple myeloma.). We eagerly await monoclonal antibody-based therapy in myeloma, as we have had for years in lymphoma. These agents attack the plasma cell in a different way, and, encouragingly, what we heard at ASH is that they are not only tolerable but effective. They will certainly be additive to our arsenal, said Sonja Zweegman, MD, PhD, of VU University Medical Center in Amsterdam, The Netherlands, who moderated a session on new agents in myeloma.. Elotuzumab. Paul G. Richardson, MD, of Dana-Farber Cancer Institute, Boston, agreed. As we all know, recognizing the complex biology of myeloma, we need more treatment options, he said.. Echoing Dr. Zweegmans excitement over monoclonal antibodies, he commented, We saw great data ...
The heavier a person is and the less exercise he or she does, the greater the likelihood of developing a specific type of colorectal cancer, a new study finds.. Researchers at the Dana-Farber Cancer Institute in Boston analyzed data on weight and physical activity from questionnaires sent every two years to more than 109,046 women who participated in the landmark Nurses Health Study, an ongoing study about womens health that is following nurses. The questionnaires also went to more than 47,684 men who participated in the Health Professionals Follow-Up Study, an ongoing study about mens health that includes more than 50,000 men who work in health care. Data collection began in 1976 for the women and in 1986 for the men.. When follow-up ended in June 2004, 2,263 cases of colorectal cancer - 842 in men and 1,421 in women - had been diagnosed. The researchers analyzed 861 of the cancers to determine if any contained a molecular biomarker, called CTNNB1, which has been linked to cancer and ...
The Albert and Mary Lasker Foundation honored three distinguished physician-scientists with a coveted award for their independent, groundbreaking research that led to the discovery of HIF1 and explained how the protein drives physiologic changes in response to hypoxia. Such changes can play a role in cancer progression and the development of other medical conditions.. Gregg L. Semenza, MD, PhD, of Johns Hopkins University School of Medicine in Baltimore, MD; Peter J. Ratcliffe, MD, of the University of Oxford and the Francis Crick Institute in the UK; and William G. Kaelin Jr., MD, of Dana-Farber Cancer Institute in Boston, MA, will share the 2016 Albert Lasker Basic Medical Research Award and the $250,000 honorarium it carries. The prize was bestowed during a September 23 ceremony in New York, NY.. In the early 1990s, Semenza was trying to explain how hypoxia triggers the production of erythropoietin, promoting the formation of red blood cells, which carry oxygen. Through a series of ...
For the first time, researchers have laid bare the full genetic blueprint of multiple prostate tumors, uncovering alterations that have never before been detected and offering a deep view of the genetic missteps that underlie the disease. The study, made possible by key advances in whole genome sequencing and analysis, points to several new prostate cancer genes and a critical category of genomic changes as important drivers of prostate cancer growth. The work was led by researchers from the Broad Institute, Dana-Farber Cancer Institute and Weill Cornell Medical College and appears in the February 10th issue of the journal Nature.. Unlike other sequencing methods that target specific sections of the genome, whole genome sequencing enables researchers to look across the entire DNA landscape of a tumor, making it possible to discern global changes and patterns. Senior authors Levi Garraway and Mark Rubin and their colleagues used this strategy to view the complete genomes of seven prostate tumors ...
The New York Times]. Over the past few decades, changes in the treatment of breast cancer amount to a revolution in patient care. And its not over yet. There was a time when the standard approach was a radicalmastectomy, which involved removal of not just the breast, but all the lymph nodes in the armpit and underlying muscles in the chest wall. This approach has been replaced by less extensive surgery that, through decades of clinical trials, has proved to be equally effective at treating patients, as well as safer and less disfiguring. Even simple mastectomies, in which most nodes and the muscles were left intact, have become far less common. Dr. J. Dirk Iglehart, director of the Susan F. Smith Center for Womens Cancers at Dana-Farber Cancer Institute in Boston, estimated that he now performs a tenth of the number of mastectomies than when he entered the field in the 1970s.. Currently, most women with early-stage breast cancer have alumpectomy; only the tumor and a small margin of ...
Background: Evidence suggests that the experience of cancer differs across racial and ethnic underserved populations. We describe the referral patterns and clinical characteristics of patients receiving care at Dana-Farber Cancer Institutes clinical outreach community cancer program, an initiative established to improve access to quality cancer care across the spectrum of the disease for medically underserved patients.. Methods: Two hundred and twenty five patients, receiving care at our community cancer care site, based within a Federally Qualified Health Center in Boston, were consented to research and enrolled between January 2012 and June 2015. The program accommodates all oncology and hematology referrals from primary care providers (PCP) at the health center. Variables of interest were collected through medical chart review and a patient intake survey that was developed for the program, and included age, gender, ethnicity, health insurance coverage, reasons for referral, presence of ...
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of CME Outfitters and Dana-Farber Cancer Institute. CME Outfitters is accredited by the ACCME to provide continuing medical education for physicians.. CME Outfitters designates this activity for a maximum of TBD AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. MOC Statement. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to TBD MOC points in the American Board of Internal Medicines (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity providers responsibility to submit participant completion ...
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of CME Outfitters and Dana-Farber Cancer Institute. CME Outfitters is accredited by the ACCME to provide continuing medical education for physicians.. CME Outfitters designates this activity for a maximum of TBD AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. MOC Statement. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to TBD MOC points in the American Board of Internal Medicines (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity providers responsibility to submit participant completion ...
First data published using amplicon-based technology to detect ALK and ROS1 fusions. Highly sensitive detection of resistance mutations provides basis for optimising therapy for patients with relapsed NSCLC. Inivata announces that new clinical data from its collaboration with Dana-Farber Cancer Institute will be presented at the World Conference on Lung Cancer (WCLC).. The study involved a blind retrospective evaluation of Inivatas InVision ctDNA liquid biopsy analysis to characterise and monitor the molecular profile of advanced non-small cell lung cancer (NSCLC) during genotype-directed therapy with osimertinib.. Inivatas technology was shown to detect a full range of genotypes, including gene rearrangements, with an exquisite sensitivity and a high specificity. It was able to detect ALK and ROS1 fusions with high sensitivity, the first time this has been shown using amplicon sequencing. As published previously, there was excellent concordance with droplet digital PCR (ddPCR).. Commenting on ...
In a Nature Letters article published in July 2017, a group from the Dana-Farber Cancer Institute led by Catherine Wu reported an exciting proof-of-principle study showing that a personal neoantigen vaccine is safe, strongly immunogenic, and capable of inducing tumor-reactive T cells.. Ott et al. Nature Letters 2017 used whole-exome sequencing of DNA from matched tumor and normal cells to identify somatic mutations and used HLA binding prediction algorithms to create personalized HLA-binding peptide sequences. Corresponding peptides were synthesized and used as immunogens administered with poly-ICLC in patients with previously untreated high-risk melanoma in a phase I study.. In conjunction with flow cytometry, the authors used Mabtech IFN-γ ELISpot assays to show that personalized neoantigen vaccines generate polyfunctional CD4- as well as CD8-specific T cell responses that persisted over time. They also showed that subsequent checkpoint blockade therapy (anti-PD1 mAb pembrolizumab) broadens ...
Some patients with a form of advanced kidney cancer benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by Dana-Farber Cancer Institute scientists.
John Heymach, MD: The RELAY study compared erlotinib and ramucirumab versus erlotinib with placebo.. Whats the preclinical rationale for the RELAY study? Well, its been known for some time that tumors with EGFR mutations upregulate VEGF and the VEGF pathway. This appears to be, at least in part, through something called the HIF pathway. HIF stands for hypoxia-inducible factor.. Normally when cells have low oxygen, they turn on this HIF pathway, and that turns on all these factors that help the cells survive. In fact, the Nobel Prize in Physiology or Medicine this past year was awarded for understanding the mechanisms underlying this HIF pathway. It was awarded to Bill Kaelin, MD at Dana-Farber Cancer Institute, as well as Peter John Ratcliffe, FRS, FMedSci and Gregg Semenza, MD, PhD, whos at Johns Hopkins Medicine for showing how this mechanism works.. Tumors with an EGFR mutation, when you turn on this HIF pathway, that leads to VEGF getting upregulated. Theyre highly dependent on the VEGF ...
For the last decade, advanced renal cell carcinoma (RCC) has been at the forefront of oncologic innovation. While there is extensive imaging research on RCC, the important themes that could shape the future of RCC imaging revolve around the use of imaging as a biomarker to predict the make-up and behavior of the disease. In an article published online in Radiology(RSNA.org/Radiology), Atul B. Shinagare, MD, of the Dana-Farber Cancer Institute, Boston, and colleagues review developments in management of advanced RCC from a radiologists perspective with the aim of enhancing the specialtys value in clinical management. Specifically, the authors describe:. • How the underlying molecular mechanisms of RCC provide specific targets for novel anticancer agents. • The relationship between the mechanisms of action of the novel anticancer agents and the imaging appearance of tumor response • Available tumor response criteria and their strengths and weaknesses. The authors also summarize the class- ...
Dr. Laurie Cohen, MD is a pediatric endocrinologist in Boston, Massachusetts. She is affiliated with Boston Childrens Hospital and Dana-Farber Cancer Institute.
Excerpted from Study finds spiritual care still rare at end of life, Chicago Tribune, by Kathleen Raven. December 26, 2012--Physicians and nurses at four Boston medical centers cited a lack of training to explain why they rarely provide spiritual care for terminally ill cancer patients - although most considered it an important part of treatment at the end of life. I was quite surprised that it was really just lack of training that dominated the reasons why, senior author Dr. Tracy Balboni, a radiation oncologist at the Dana-Farber Cancer Institute in Boston, told Reuters Health. Current U.S. palliative care guidelines encourage medical practitioners to pay close attention to religious and spiritual needs that may arise during a patients end-of-life care. However, the 204 physicians who participated in the study reported providing spiritual care to just 24 percent of their patients. Among 118 nurses, the figure was 31 percent. The 69 patients with advanced cancers who took the survey ...
Im posting this on behalf of a friend. Please respond to the address below (jkim at isdtcp3.hwc.ca) and not to me. We are involved in a study examining the effects of psychological stress on the immune system. One aspect involves measurement of the levels of acute phase proteins from the serum of rats and humans.... Does anyone know a commercial vendor who sells kits for these proteins which include C-reactive protein, serum amyloid A, transferrin, alpha 1-acid glycoprotein, haptoglobin, hemopexin, alpha 2-macroglobulin (rat) and alpha 1-antitrypsin. Any help or leads would be greatly appreciated. John E. Kim (PhD) Health Canada 775 Brookfield Rd Ottawa, Ontario Canada K1A 1C1 Ph 613-954-7804 fax:613-941-1734 e-mail jkim at isdtcp3.hwc.ca -- Ian York (york at mbcrr.harvard.edu) Dana-Farber Cancer Institute, 44 Binney St., Boston MA 02115 Phone (617)-632-3921 Fax (617)-632-2627 ...
Researchers from the Dana-Farber Cancer Institute [1] engineered telomerase-deficient mice by knocking out the TERT gene, which codes the telomerase enzyme. These mice, inbred through several generations, showed considerable damage to several organs, tissue atrophy, and half the life span of normal mice. The researchers then devised a clever way to reactivate the enzyme by activating TERT transcription only in the presence of a molecule called 4-OHT. In the presence of 4-OHT, in vitro cell cultures showed that the telomerese ends lengthened and cell proliferation resumed. Furthermore, after a 4-week treatment with the 4-OHT molecule, the degenerative damage induced by the lack of telomerase in the the knock-out mice was considerably reversed and their life span lengthened ...
Technique detects technical biases that otherwise confound test results A new computational method can improve the accuracy of gene expression analyses, which are increasingly used to diagnose and monitor cancers and are a major tool for basic biological research. Researchers from Carnegie Mellon University, Stony Brook University and Dana-Farber Cancer Institute said their method, called ...
Meet Doctor Richard M Stone. Here are his vitals: Hes board certified, specializing in Internal Medicine with expertise in several areas. Doctor Stone is a highly experienced doctor, with 27 years of practice in the field He has won a number of awards, including Castle Connolly Americas Top Doctors® 2002 and Castle Connolly Americas Top Doctors® for Cancer 2009. Is affiliated with a highly rated hospital. Graduated from top rated Harvard University. He completed his fellowship at Dana-Farber Cancer Institute in 1987. Doctor Stone is a published author, having articles in peer reviewed journals. He accepts new patients. He has a number of insurance plans accepted. Use Vitals.com to examine Doctor Richard M Stone from Boston, Massachusetts. See patient comments make an appointment or even let us help you to prepare for your visit. Vitals .com where doctors are examined.. ...
Éric A. Cohen (born March 19, 1958) is a Canadian molecular virologist whose research is focused on human immunodeficiency virus (HIV)-host interactions that govern viral replication and persistence. Cohen graduated from Collège Jean-de-Brébeuf of Montréal in 1977 with a college diploma in Health Sciences. He received a B.Sc. in Biochemistry from McGill University in 1981 and a Ph.D. in Molecular Biology from Université de Montréal in 1987. As a Ph.D. student, he worked on fundamental aspects of herpes simplex virus replication and transformation under the direction of Yves Langelier. In 1986, he joined the laboratory of William A. Haseltine at the Dana-Farber Cancer Institute and Harvard Medical School as a postdoctoral fellow, working on fundamental aspects of HIV structure and function to uncover new targets for antiviral therapy. His postdoctoral work led to the identification of two HIV-1 non-structural proteins, named Viral Protein U (Vpu) and Viral Protein R (Vpr), part of a new ...
Looking for an expert Executive Director in Business Development? Alyssa ODriscoll has prior experience at Intermountain Healthcare, Dana-farber Cancer Institute, Tourism Cares and works in Salt Lake City. Alyssa can consult, speak or advise you on Fundraising/Business Development, Strategic Planning, Marketing/Communications/PR.
topoption opiniones Powered By markets slide worldwide amid u.s. budget battleD e d; forexpros forexservice forexsystems24. Wirtschaft kostenlos artikel Software deutschland und Michail Sitkovsky, Dana-Farber Cancer Institute, Boston, USA. Core Facilities . global proteomic dynamics in a cell, tissue . same time serve emerging markets as well budget of 6 million euros by the European The TIB is then followed by sliding the transducer ceph- implants are a way to fight periprostetic. This world-wide first dictionary of tribology should be of particular benefit to Technischer Berater war er für die technische Unterstützung der slide (US). Achslagergehåuse (n): axle box case. (GB); axle box housing .. AI-polymere (pl): amide-imide poly- into the market /to (Vertrieb) capital budget (Betriebsw).5 Aug 2013 Amerika American Civil War np Amerikanischer Bürgerkrieg:Sezessionskrieg .. Gliwice np Gleiwitz Global Positioning System np Global Positioning System amethyst n Amethyst amiable a ...
|br /| David Reardon, M.D., clinical director at the Center for Neuro-oncology at the Dana-Farber Cancer Institute, breaks down a common misconception that many people have about glioblastoma (GBM).
Results A total of 94 cases (48 boys and 46 girls) of AP, clinician-diagnosed from April 2013 to April 2014, fulfilled the diagnostic criteria. The median age of diagnosis was 11.2 years (range 1.30-14.89 years). White children accounted for 60% of cases compared to 40% from ethnic minorities (71% Asian and 13% Black). Pakistani children alone made up 19% of the cohort. The reported incidence of AP in children under age 15 in the UK was 0.78 per 100,000 (95% CI 0.62-0.96). Of the 94 cases: 36 (38%) were idiopathic, drugs 18 (19%), gallstones 12 (13%), hereditary 7 (7.5%), organic acidaemia 7 (7.5%), anatomical anomalies 4 (4%), viral infections 3 (3%), vasculitis 3 (3%), trauma 1 (1%) and others 3 (3%). The most common drug associations were asparaginase (28%), azathioprine (17%) and sodium valproate (17%). Of the 12 gallstone-associated cases, 5 were boys; body weight of 5 cases were above the 91st centile (4 were above the 98th centile). Overall, 6 of 7 organic acidaemia cases (86%) and 3 of 5 ...
TY - JOUR. T1 - Rationale for an international consortium to study inherited genetic susceptibility to childhood acute lymphoblastic leukemia. AU - Sherborne, Amy L.. AU - Hemminki, Kari. AU - Kumar, Rajiv. AU - Bartram, Claus R.. AU - Stanulla, Martin. AU - Schrappe, Martin. AU - Petridou, Eleni. AU - Semsei, Ágnes F.. AU - Szalai, Csaba. AU - Sinnett, Daniel. AU - Krajinovic, Maja. AU - Healy, Jasmine. AU - Lanciotti, Marina. AU - Dufour, Carlo. AU - Indaco, Stefania. AU - El-Ghouroury, Eman A.. AU - Sawangpanich, Ruchchadol. AU - Hongeng, Suradej. AU - Pakakasama, Samart. AU - Gonzalez-Neira, Anna. AU - Ugarte, Evelia L.. AU - Leal, Valeria P.. AU - Espinoza, Juan P M. AU - Kamel, Azza M.. AU - Ebid, Gamal T A. AU - Radwan, Eman R.. AU - Yalin, Serap. AU - Yalin, Erdinc. AU - Berkoz, Mehmet. AU - Simpson, Jill. AU - Roman, Eve. AU - Lightfoot, Tracy. AU - Hosking, Fay J.. AU - Vijayakrishnan, Jayaram. AU - Greaves, Mel. AU - Houlston, Richard S.. PY - 2011/7. Y1 - 2011/7. N2 - Acute ...
Lehtinen, S. S., Huuskonen, U. E., Harila-Saari, A. H., Tolonen, U., Vainionpää, L. K. and Lanning, B. M. (2002), Motor nervous system impairment persists in long-term survivors of childhood acute lymphoblastic leukemia. Cancer, 94: 2466-2473. doi: 10.1002/cncr.10503 ...
Hikmet Geckil is a Turkish academic who received PhD degree in Molecular Biology (with Benjamin C. Stark) at IIT. His research is in the area of genetic engineering. His current affiliation is with the Department of Molecular Biology and Genetics at Inonu University Research in Geckils GE Laboratory is primarily based on the function of Vitreoscilla hemoglobin (VHb), the first prokaryotic hemoglobin. Using VHb, Geckils group engineered various bacteria for the purpose of producing industrially important products ranging from microbial fuels butanediol, acetoin to drugs used in Alzheimers and Parkinson disease (e.g., dopa, dopamine) and to asparaginase, an enzyme used in cancer chemotherapy. One of the recent endeavors of his laboratory is to understand the role of mTOR signal complex on the aerobic glycolysis of cancer cells also known as Warburg effect, one of the 10 hallmarks of all cancers. Geckil has published in the areas of biochemistry, biomedicine, and biotechnology, and has over 30 ...
Flammulina velutipes creates asparaginase. Plinabulin is a fungal isolate derivative currently being researched for anticancer ...
L-asparaginase is an enzyme that in humans is encoded by the ASRGL1 gene. The ASRGL1 protein consists of 308 amino acids and is ... "Entrez Gene: ASRGL1 asparaginase like 1". CS1 maint: discouraged parameter (link) Li, Wenzong; Cantor, Jason R.; Yogesha, S. D ... The ASRGL1 enzyme has both L-asparaginase and beta-aspartyl peptidase activity and may be involved in the production of L- ... Bush LA, Herr JC, Wolkowicz M, Sherman NE, Shore A, Flickinger CJ (2002). "A novel asparaginase-like protein is a sperm ...
Anonymous (2012). "Asparaginase erwinia chrysanthemi (erwinaze) for all". Medical Letter on Drugs and Therapeutics. 54 (1388): ... Most noble of its contributions is an enzyme, asparaginase, being used in conjunction with other chemotherapeutic agents for ... coli derived asparaginase Elspar or pegaspargase (Oncaspar). Secondly, with a strong governmental push towards increasing ...
Jerebzoff-Quintin, Simonne; Jerebzoff, Stephan (1985). "L-Asparaginase activity in Leptosphaeria michotii. Isolation and ... "Crystal Structure and Allosteric Regulation of the Cytoplasmic Escherichia coli l-Asparaginase I". Journal of Molecular Biology ...
Lanvers-Kaminsky, Claudia (2017-03-01). "Asparaginase pharmacology: challenges still to be faced". Cancer Chemotherapy and ...
... is hydrolyzed to aspartate by asparaginase. Aspartate then undergoes transamination to form glutamate and ...
Shrivastava A, Khan AA, Shrivastav A, Jain SK, Singhal PK (2012). "Kinetic studies of L-asparaginase from Penicillium digitatum ... Penicillium is a potential source of the leukemia medicine asparaginase. Some countries have approved Beta-glucan fungal ...
For children with low-risk ALL, standard therapy usually consists of three drugs (prednisone, L-asparaginase, and vincristine) ... other drug plans may include L-asparaginase or cyclophosphamide. ...
"Selective apoptosis of natural killer-cell tumours by l-asparaginase". British Journal of Haematology. 130 (6): 860-868. doi: ...
Acquired deficiencies in antithrombin III and C protein during treatment with L-asparaginase]. „Arch Fr Pediatr". 44 (3), s. ...
The most common treatment is a combination of cyclophosphamide, vincristine, prednisone, L-asparaginase, and doxorubicin. Other ...
Bacillus is utilized in the production of the chemotherapy medicine L-asparaginase. Bacillus subtilis is utilized in the ... a bacterium used to produce the chemotherapy medicine asparaginase Fungal isolates Medicinal molds Sponge isolates Streptomyces ...
... has been used in conjunction with phenol red to monitor the fungal asparaginase enzyme activity with phenol ... ISBN 978-0-470-40753-0. Dhale, Mohan (July 2014). "A comparative rapid and sensitive method to screen l-asparaginase producing ...
... amphilecti AMI6 isolated from mangrove sediments produces thermostable glutaminase-free L-asparaginase. Arahal DR, ... structural modeling and characterization of a novel glutaminase-free L-asparaginase from Cobetia amphilecti AMI6". ...
Kavitha, A; Vijayalakshmi, M (2009). "Optimization and purification of L-asparaginase produced by Streptomyces tendae TK-VL_333 ...
FraE is specific for F-Asn and cannot function as a general periplasmic asparaginase like ansB. fraA encodes a transporter of ... fraE encodes the periplasmic fructose-asparaginase FraE that removes ammonia from F-Asn to form fructose-aspartate (F-Asp). ... Mutations in fraE do not prevent F-Asn utilization due to redundancy conferred by the ansB gene that codes for the asparaginase ... an asparaginase homolog, contributes to fructose-asparagine but not asparagine utilization". Journal of Bacteriology. 199 (22 ...
... who noted that genes associated with asparaginase sensitivity failed to score in their genome-wide screen of asparaginase- ... 2019) used this method to identify a synthetic lethal interaction between the chemotherapy drug asparaginase and two genes in ... April 2019). "Synthetic Lethality of Wnt Pathway Activation and Asparaginase in Drug-Resistant Acute Leukemias". Cancer Cell. ...
It is a modified version of the enzyme asparaginase which has undergone PEGylation. It works by breaking down asparagine, ...
asparaginase (better tolerance in people in pediatric care). *daunorubicin (used in Adult ALL) ...
1994). "Hyperglycemia, ketoacidosis and other complications of L-asparaginase in children with acute lymphoblastic leukemia". J ... L-asparaginase, and antipsychotics. The acute administration of stimulants such as amphetamines typically produces ...
... asparagin)ase". Biochemistry International. 12 (3): 413-20. PMID 3707592.. ...
This can be discouraged by heating at a lower temperature, adding asparaginase, or injecting carbon dioxide. In the cooking ...
Insolubilization of L-Asparaginase by covalent attachment to nylon tubing (Ph.D.). The University of Texas at Austin. OCLC ... Allison, James Patrick (1973). Studies on bacterial asparaginases: I. Isolation and characterization of a tumor inhibitory ...
As a result, L-asparaginase is a common chemotherapy drug utilized in the treatment of ALL and may have applications in other ... For example, in mouse models, 24 hours after exposure to L-asparaginase, tumors resistant to the depletion responded with 5- to ... However, the opposite effect is visible in cases of asparaginase resistant cancers. In these resistant cancers, the effect of ... It has been further demonstrated in mouse model systems that repeated subculturing of L-asparaginase sensitive tumor cells in ...
SurEstructural domain has a similar topology to the N-terminal protein domain of the glutaminase/asparaginase family. The C- ...
The halotolerant Cobetia amphilecti AMI6 produces glutaminase-free L-asparaginase (CobAsnase) with a molecular mass of 37 kDa ... structural modeling and characterization of a novel glutaminase-free L-asparaginase from Cobetia amphilecti AMI6". ...
Gentille C, Qin Q, Barbieri A, Ravi PS, Iyer S (2017). "Use of PEG-asparaginase in monomorphic epitheliotropic intestinal T- ...
It is also used to induce remission in ALL with dexamethasone and L-Asparaginase, and in combination with prednisone to treat ...
Approval was based on a demonstration of the achievement and maintenance of nadir serum asparaginase activity above the level ... Calaspargase pegol is an engineered protein consisting of the E. coli-derived enzyme L-asparaginase II conjugated with ... succinimidyl carbonate monomethoxypolyethylene glycol (pegol). The L-asparaginase portion hydrolyzes L-asparagine to L-aspartic ...
"Optimization of Culture Conditions for Production of the Anti-Leukemic Glutaminase Free L-Asparaginase by Newly Isolated NEAE- ...
Asparaginase Erwinia Chrysanthemi Injection: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Before taking asparaginase erwinia chrysanthemi,. *tell your doctor and pharmacist if you are allergic to asparaginase erwinia ... asparaginase [Elspar] or pegaspargase [Oncaspar]). Asparaginase erwinia chrysanthemi is an enzyme that interferes with natural ... Asparaginase erwinia chrysanthemi comes as a powder to be added to fluid and injected into a muscle by a doctor or nurse in a ...
Asparaginase is used to treat acute lymphocytic leukemia (ALL). It works by starving tumor cells of needed nutrients and ...
Make research projects and school reports about Asparaginase easy with credible articles from our FREE, online encyclopedia and ... Asparaginase Gale Encyclopedia of Cancer COPYRIGHT 2002 The Gale Group Inc.. Asparaginase. Definition. Asparaginase (also known ... Asparaginase is an enzyme made from the bacteria escherichia coli (E. coli). In this country, two forms of asparaginase are ... coli asparaginase. Asparaginase kills cancer cells by depleting a certain protein in the blood (L-asparagine) that is necessary ...
Type I (cytosolic) L-asparaginase (IPR041725). Short name: L-asparaginase_I Overlapping homologous superfamilies *Asparaginase/ ... Asparaginase/glutaminase-like (IPR006034) *Type I L-asparaginase family (IPR006033) *Type I (cytosolic) L-asparaginase ( ... Many bacterial L-asparaginases have both L-asparagine and L-glutamine hydrolysis activities, to a different degree, and some of ... Asparaginases (amidohydrolases, EC:3.5.1.1) are enzymes that catalyze the hydrolysis of asparagine to aspartic acid and ammonia ...
Administration of either Escherichia coli asparaginase or guinea pig serum to C3H/HE mice with the 6C3HED lymphosarcoma is ... This decrease in cellular glycine concentration does not occur in a tumor resistant to asparaginase. The inhibition of the ... lymphosarcoma by asparaginase can be reversed by intraperitoneal injection of asparagine or glycine. This reversal appears to ...
Asparaginase is an enzyme that is used as a medication and in food manufacturing. As a medication, L-asparaginase is used to ... Type I L-asparaginase protein may use the morpheein model of allosteric regulation. Normal asparaginase costs less than its ... The most common use of asparaginases is as a processing aid in the manufacture of food. Asparaginases are used as a food ... Crasnitin has been discontinued.) Spectrila is a new recombinant E. coli asparaginase. Asparaginase produced by Dickeya ...
Find patient medical information for asparaginase injection on WebMD including its uses, side effects and safety, interactions ... Asparaginase Solution, Reconstituted (Recon Soln) Common Brand(S): Elspar Generic Name(S): asparaginase View Free Coupon * Uses ... You should not become pregnant while using asparaginase. Asparaginase may harm a pregnant woman and her unborn baby. Ask about ... Who should not take Asparaginase Solution, Reconstituted (Recon Soln)? * Does Asparaginase Solution, Reconstituted (Recon Soln ...
This medicine may cause a serious type of allergic reaction called anaphylaxis. Anaphylaxis can be life-threatening and requires immediate medical attention. Tell your doctor or nurse right away if you or your child have chills, fever, lightheadedness, dizziness, or fainting, fast, pounding heartbeat, swelling of the face, tongue, and throat, or trouble breathing after you receive the medicine. Using this medicine while you are pregnant can harm your unborn baby. If you are a woman who can bear children, your doctor may give you a pregnancy test before you start using this medicine to make sure you are not pregnant. Use an effective form of birth control during treatment and for at least 3 months after your last dose to keep from getting pregnant. If you think you have become pregnant, tell your doctor right away. Pancreatitis may occur while you are using this medicine. Tell your doctor right away if you or your child have sudden and severe stomach pain, chills, constipation, nausea, vomiting, ...
Asparaginase (Erwinia chrysanthemi) reference guide for safe and effective use from the American Society of Health-System ... Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer ... L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer. 2011; 117:238-49. [PubMed ... Cautions for Asparaginase (Erwinia chrysanthemi). Contraindications. * History of serious thrombosis with prior asparaginase ...
PEG-L-asparaginase (Pegaspargase) chemotherapy side effects, how its given, how it works, precautions and self care tips for ... The enzyme asparaginase breaks down asparagine in the body. Since the cancer cells cannot make more asparagine, they die. ... Pegaspargase is a modified version of the enzyme asparaginase. When pegaspargase breaks down asparagine it is broken down into ... You will be checked regularly by your doctor while you are taking asparaginase, to monitor side effects and check your response ...
A Moderate Drug Interaction exists between asparaginase erwinia chrysanthemi and NeoProfen. View detailed information regarding ... ibuprofen asparaginase Erwinia chrysanthemi Applies to: NeoProfen (ibuprofen) and asparaginase erwinia chrysanthemi ... Using ibuprofen with asparaginase Erwinia chrysanthemi may increase your risk of blood clots or bleeding. Talk to your doctor ... Drug Interactions between asparaginase erwinia chrysanthemi and NeoProfen. This report displays the potential drug interactions ...
For this reason asparaginase should only be administered in a hospital setting. Asparaginase often has a negative effect on ... Asparaginase (Erwinaze®) is an enzyme that breaks down (disassembles) the amino acid asparagine which is needed for cell ... Asparaginase (Erwinaze®) is administered through use of a powder that is to be mixed and injected intravenously or directly ... By reducing free asparagine in the body, asparaginase treatment results in a depletion of cancerous cells while normal cells ...
Asparaginase is an antineoplastic agent used in combination with other medications in the treatment of Acute Lymphocytic ... How to Take Asparaginase. Asparaginase is given by intravenous (into a vein) infusion or as an injection given into a big ... About: Asparaginase (Erwinia, Asparaginase Erwinia Chrysanthemi, Erwinaze). All cells in the body need the amino acid ... Asparaginase can be given in various dosing schedules, depending on the regimen and the type of asparaginase being used. ...
In enzymology, a glutamin-(asparagin-)ase (EC 3.5.1.38) is an enzyme that catalyzes the chemical reaction L-glutamine + H2O ... and properties of Achromobacteraceae glutaminase-asparaginase with antitumor activity". J. Biol. Chem. 247 (1): 84-90. PMID ...
Find patient medical information for Asparaginase (Erwinia Chrysanthemi) Injection on WebMD including its uses, side effects ... Asparaginase (Erwinia Chrysan) Solution, Reconstituted (Recon Soln). GENERIC NAME(S): Asparaginase (Erwinia Chrysan) ... You should not become pregnant while using erwinia asparaginase. Erwinia asparaginase may harm a pregnant woman and her unborn ... Erwinia asparaginase is used to treat acute lymphocytic leukemia (ALL). It works by starving tumor cells of needed nutrients ...
IPR006034, Asparaginase/glutaminase-like. IPR027475, Asparaginase/glutaminase_AS2. IPR027474, L-asparaginase_N. IPR037152, ... IPR006034, Asparaginase/glutaminase-like. IPR027475, Asparaginase/glutaminase_AS2. IPR027474, L-asparaginase_N. IPR037152, ... AsparaginaseInterPro annotation. ,p>Information which has been generated by the UniProtKB automatic annotation system, without ... 60 kDa lysophospholipase, LysoLP, EC 3.1.1.5 (Lysophospholipase-transacylase) [Includes: L-asparaginase, EC 3.5.1.1 (L- ...
Measure asparaginase activity in lysates from yeast or bacteria in only 40 minutes. ... Metabolization of asparaginase prevents acrylamide formation in fried foods (Maillard reaction).. Other asparaginases are used ... direct and automation-ready procedure for measuring asparaginase activity in biological samples. In the assay, Asparaginase ... Asparaginase does not occur naturally in humans but is found in bacteria, plants and many animals (e.g. guinea pigs).. ...
These findings suggest that asparaginase II is produced by E. coli A-l in response to low concentrations of ammonia and that ... It is suggested that E. coli A-l produced L-asparaginase in order to obtain ammonia for the synthesis of glutamine from ... The addition of glucose to the same medium before asparaginase II activity was detected resulted in the production of acid by E ... Glucose was exhausted two hours before ammonia and three hours before asparaginase II activity was detected. The concentration ...
Common brand names: Elspar Summary of Interactions with Vitamins, Herbs, & Foods What Are Nutrient Interactions Types of interactions: Beneficial Adverse Check Replenish Depleted Nutrients Magnesium and Potassium The chemotherapy drug cisplatin may cause excessive loss of magnesium and potassium in the urine...
In this study, a different form of Asparaginase will be used, called PEG-Asparaginase (also called Oncospar), which remains in ... In children there is some early information that PEG-Asparaginase produces fewer antibodies than E.coli Asparaginase. Therefore ... PEG-Asparaginase has recently been approved by the FDA to treat ALL. Most of the experience with the drug has been in children ... Intensified Post Remission Therapy Containing PEG-Asparaginase. The safety and scientific validity of this study is the ...
Browse our L-Asparaginase Antibodies all backed by our Guarantee+. ... anti-L asparaginase 1 antibody, anti-L asparaginase 2 antibody, anti-L asparaginase I antibody, anti-L asparaginase II antibody ... anti-L-Asparaginase antibody, anti-ansB antibody, anti-AnsA antibody, anti-Asparaginase antibody, anti-Colaspase antibody, anti ... L-Asparaginase Antibodies. We offer L-Asparaginase Antibodies for use in common research applications: ELISA, ...
Asparaginase Erwinia chrysanthemi is used to treat acute lymphocytic lymphoma. Asparaginase Erwinia chrysanthemi may also be ... Asparaginase is a cancer medication that interferes with the growth and spread of cancer cells in the body. ... What is asparaginase Erwinia chrysanthemi?. Asparaginase is a cancer medication that interferes with the growth and spread of ... Asparaginase Erwinia chrysanthemi is used to treat acute lymphocytic lymphoma.. You should not receive asparaginase Erwinia ...
N(4)-(Beta-N-acetylglucosaminyl)-L-asparaginase (EC:3.5.1.26*Search proteins in UniProtKB for this EC number. ... sp,Q47898,ASPG_ELIMR N(4)-(Beta-N-acetylglucosaminyl)-L-asparaginase OS=Elizabethkingia miricola OX=172045 PE=1 SV=1 ...
Interestingly, E289 belongs to a loop that is very variable in L-asparaginases from the structure, sequence and length point of ... In contrast to other known L-asparaginases, Helicobacter pylori CCUG 17874 type II enzyme (HpASNase) is cooperative and has a ... Bacterial asparaginases (amidohydrolases, EC 3.5.1.1) are important enzymes in cancer therapy, especially for Acute ... In contrast to other known L-asparaginases, Helicobacter pylori CCUG 17874 type II enzyme (HpASNase) is cooperative and has a ...
Putative L-asparaginase. A, C. 177. Escherichia coli. Mutation(s): 1 Gene Names: ybiK. EC: 3.5.1.1 (PDB Primary Data), 3.4.19.5 ... Putative L-asparaginase. B, D. 143. Escherichia coli. Mutation(s): 0 Gene Names: ybiK. EC: 3.5.1.1 (PDB Primary Data), 3.4.19.5 ... Plant-type L-asparaginases hydrolyze the side-chain amide bond of L-asparagine or its beta-peptides. They belong to the N- ... Plant-type L-asparaginases hydrolyze the side-chain amide bond of L-asparagine or its beta-peptides. They belong to the N- ...
l-Asparaginase is a key therapeutic agent for treatment of childhood acute lymphoblastic leukemia (ALL). There is wide ... Here, we now report that 2 lysosomal cysteine proteases present in lymphoblasts are able to degrade l-asparaginase. Cathepsin B ... The mechanisms of therapeutic failure with l-asparaginase remain speculative. ... CTSB), which is produced constitutively by normal and leukemic cells, degraded asparaginase produced by Escherichia coli ( ...
Downloading a figure as powerpoint requires a browser with javascript support. Enable javascript and try again For help please contact [email protected] ...
Biochemical and Pharmacological Studies with Asparaginase in Man. Takao Ohnuma, James F. Holland, Arnold Freeman and Lucius F. ... Biochemical and Pharmacological Studies with Asparaginase in Man. Takao Ohnuma, James F. Holland, Arnold Freeman and Lucius F. ... Biochemical and Pharmacological Studies with Asparaginase in Man. Takao Ohnuma, James F. Holland, Arnold Freeman and Lucius F. ... Biochemical and Pharmacological Studies with Asparaginase in Man Message Subject (Your Name) has forwarded a page to you from ...
Copyright 2020 © Index-China Medicine shares knowledge about good medicine and remedies. Website is in testing process, content is for reference only. All information about drug use should be consulted with a qualified physician. ...
The PDB archive contains information about experimentally-determined structures of proteins, nucleic acids, and complex assemblies. As a member of the wwPDB, the RCSB PDB curates and annotates PDB data according to agreed upon standards. The RCSB PDB also provides a variety of tools and resources. Users can perform simple and advanced searches based on annotations relating to sequence, structure and function. These molecules are visualized, downloaded, and analyzed by users who range from students to specialized scientists.
  • Asparaginase produced by Dickeya dadantii (formerly called Erwinia chrysanthemi) instead is known as crisantaspase (BAN), and is available in the United Kingdom under the trade name Erwinase. (wikipedia.org)
  • Asparaginase erwinia chrysanthemi is an enzyme that interferes with natural substances necessary for cancer cell growth. (medlineplus.gov)
  • Asparaginase erwinia chrysanthemi comes as a powder to be added to fluid and injected into a muscle by a doctor or nurse in a medical facility. (medlineplus.gov)
  • tell your doctor and pharmacist if you are allergic to asparaginase erwinia chrysanthemi, any other medications, or any of the ingredients in asparaginase erwinia chrysanthemi powder. (medlineplus.gov)
  • Your doctor probably will not want you to receive asparaginase Erwinia chrysanthemi . (medlineplus.gov)
  • If you become pregnant while receiving asparaginase erwinia chrysanthemi, call your doctor. (medlineplus.gov)
  • If you miss an appointment to receive a dose of asparaginase erwinia chrysanthemi, call your doctor right away. (medlineplus.gov)
  • Asparaginase erwinia chrysanthemi may cause side effects. (medlineplus.gov)
  • Your doctor will order certain lab tests to check your body's response to asparaginase erwinia chrysanthemi. (medlineplus.gov)
  • Another natural form of asparaginase made from the plant bacteria erwinia carotovora is known by the brand name Erwinar and can be specially obtained for patients who develop a severe allergy to E. coli asparaginase. (encyclopedia.com)
  • Add 1 or 2 mL of sterile, preservative-free 0.9% sodium chloride injection to a vial containing 10,000 units of asparaginase (Erwinia chrysanthemi) to provide a solution containing 10,000 or 5000 units/mL, respectively. (drugs.com)
  • Using ibuprofen with asparaginase Erwinia chrysanthemi may increase your risk of blood clots or bleeding. (drugs.com)
  • List Asparaginase (Erwinia Chrysan) Solution, Reconstituted (Recon Soln) side effects by likelihood and severity. (webmd.com)
  • Before receiving erwinia asparaginase , tell your doctor or pharmacist if you are allergic to it or if you have any other allergies . (webmd.com)
  • What is the most important information I should know about asparaginase Erwinia chrysanthemi? (adventisthealthcare.com)
  • You should not receive asparaginase Erwinia chrysanthemi if you are allergic to it, or if you have received asparaginase (Elspar) in the past and it caused you to have serious pancreas problems, a blood clot, or serious bleeding problems. (adventisthealthcare.com)
  • Asparaginase Erwinia chrysanthemi may also be used for other purposes not listed in this medication guide. (adventisthealthcare.com)
  • What should I discuss with my healthcare provider before taking asparaginase Erwinia chrysanthemi? (adventisthealthcare.com)
  • It is not known whether asparaginase Erwinia chrysanthemi will harm an unborn baby. (adventisthealthcare.com)
  • You should not breast-feed while you are using asparaginase Erwinia chrysanthemi. (adventisthealthcare.com)
  • How should I take asparaginase Erwinia chrysanthemi? (adventisthealthcare.com)
  • Asparaginase Erwinia chrysanthemi is injected into a muscle. (adventisthealthcare.com)
  • Call your doctor for instructions if you miss an appointment for your asparaginase Erwinia chrysanthemi injection. (adventisthealthcare.com)
  • What should I avoid while taking asparaginase Erwinia chrysanthemi? (adventisthealthcare.com)
  • What are the possible side effects of asparaginase Erwinia chrysanthemi? (adventisthealthcare.com)
  • What other drugs will affect asparaginase Erwinia chrysanthemi? (adventisthealthcare.com)
  • Cathepsin B (CTSB), which is produced constitutively by normal and leukemic cells, degraded asparaginase produced by Escherichia coli (ASNase) and Erwinia chrysanthemi. (jci.org)
  • DUBLIN , Dec. 20, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved the intravenous administration of Erwinaze® (asparaginase Erwinia chrysanthemi ). (prnewswire.co.uk)
  • The FDA approval was based on a pharmacokinetic study of intravenous asparaginase Erwinia chrysanthemi following hypersensitivity to E coli -derived asparaginase. (prnewswire.co.uk)
  • Erwinaze® (asparaginase Erwinia chrysanthemi ) is currently approved in the U.S. for administration via intramuscular injection or via intravenous infusion in conjunction with chemotherapy. (prnewswire.co.uk)
  • Erwinaze is derived from the bacterium Erwinia chrysanthemi and is therefore immunologically distinct from E. coli -derived asparaginase and suitable for patients with hypersensitivity to E. coli -derived treatments 3 . (prnewswire.co.uk)
  • 3 Three enzyme preparations are used: (i) native l-asparaginase derived from Escherichia coli (EcA) or (ii) in the pegylated form (EcPA) and (iii) isolated l-asparaginase from Erwinia chrysanthemi (ErA). (scielo.br)
  • The development of L-asparaginase from Erwinia chrysanthemi (Erwinase, EUSA Pharma) is an outcome of such efforts (8). (pharmtech.com)
  • Asparaginase extracted from erwinia sp. (cancercare.ns.ca)
  • erwinia source asparaginase limited to patient with allergy to E.coli proteins. (cancercare.ns.ca)
  • You should not receive it if you had an allergic reaction to asparaginase Erwinia chrysanthemi, or if you had bleeding problems, blood clots, or pancreas problems from prior treatment with asparaginase. (limamemorial.org)
  • l -Asparaginase from Erwinia carotovora . (springer.com)
  • Comparison between two Erwinia carotovora l -asparaginase II constructions: cloning, heterologous expression, purification, and kinetic characterization. (springer.com)
  • Comparison of Escherichia coli asparaginase with Erwinia -asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trials. (springer.com)
  • Asparaginase Erwinia chrysanthemi comes as a powder to be added to fluid and injected into a muscle (IM) or into the vein (IV) by a healthcare professional. (rxwiki.com)
  • In order to compare costs of PEGasparaginase, Erwinia asparaginase and native E. coli asparaginase, we performed a cost-analysis in the Dutch Childhood Oncology Group ALL-10 medium-risk group intensification protocol. (haematologica.org)
  • The costs were significantly higher ($113,558) in case of allergy (n=20) necessitating a switch to Erwinia asparaginase. (haematologica.org)
  • Intensification treatment with native E. coli asparaginase, followed by a switch to PEGasparaginase, and subsequently to Erwinia asparaginase in case of allergy had similar overall costs compared to the treatment with PEGasparaginase as the first-line drug (followed by Erwinia asparaginase in the case of allergy). (haematologica.org)
  • Asparaginase costs are mainly determined by the percentage of patients who are allergic and require a switch to Erwinia asparaginase. (haematologica.org)
  • Currently, several asparaginase preparations are available on the market: these are derived from Escherichia coli in its native form (Paronal or Asparaginase medac) or as a pegylated enzyme (PEGasparaginase, Oncaspar) or extracted from Erwinia chrysanthemi ( Erwinia asparaginase, Erwinase). (haematologica.org)
  • 9 In the case of allergic reactions to PEGasparaginase, Erwinia asparaginase is given instead. (haematologica.org)
  • Erwinia asparaginase is given three times per week. (haematologica.org)
  • The different dose schedules for native E. coli asparaginase, PEGasparaginase and Erwinia asparaginase are based on differences in the pharmacokinetics of the three products. (haematologica.org)
  • In patients receiving Erwinia asparaginase, triglyceride levels increased in the first weeks as well, but no grade 3/4 dyslipidemia was found. (eur.nl)
  • Here, we report successful challenges using native Escherichia coli asparaginase after previous hypersensitivity reactions to both PEGylated E. coli asparaginase and Erwinia asparaginase. (springermedizin.de)
  • Both patients developed hypersensitivity reactions to PEGylated E. coli asparaginase and Erwinia asparaginase early in treatment, and they were challenged with native E. coli asparaginase. (springermedizin.de)
  • Asparaginase made from other bacteria (Erwinia chrysanthemi) was approved for use in the United States in 2011 and is available under the brand name Erwinaze. (wikimd.org)
  • RYLAZE (asparaginase erwinia chrysanthemi (recombinant)-rywn) is available for purchase from the authorized Specialty Distributors listed below. (rylaze.com)
  • Asparaginase Erwinia chrysanthemi and pegaspargase are considered not medically necessary when the above criteria are not met and for all other indications. (cchmedicalpolicies.com)
  • and (2) Asparaginase Erwinia chrysanthemi (Erwinaze), derived from the gram-negative bacillus bacterium Erwinia chrysanthemi . (cchmedicalpolicies.com)
  • ASPARAGINASE ERWINIA CHRYSANTHEMI (er win e uh as PAR a jin ase) is used to treat acute lymphocytic leukemia (ALL). (kramesonline.com)
  • Asparaginase is an enzyme made from the bacteria escherichia coli (E. coli). (encyclopedia.com)
  • Administration of either Escherichia coli asparaginase or guinea pig serum to C3H/HE mice with the 6C3HED lymphosarcoma is followed by depression of glycine in the tumor. (sciencemag.org)
  • To substitute for a dose of native (nonconjugated) asparaginase (Escherichia coli): 25,000 units/m 2 for each scheduled dose of native asparaginase (Escherichia coli). (drugs.com)
  • Growth of Escherichia coli A-l under aerobic conditions in an enriched medium with a total amount of 0.2 per cent glucose was biphasic and asparaginase II activity was detected after depletion of ammonia from the growth medium in the second phase of growth. (unt.edu)
  • Crystallographic studies of plant-type asparaginases have focused on an Escherichia coli homologue (EcAIII), which has been crystallized in several crystal forms. (rcsb.org)
  • The biochemical and pharmacological effects of Escherichia coli asparaginase were studied in 45 patients with leukemia and solid tumors. (aacrjournals.org)
  • L-asparaginase derived from Escherichia coli has been used in the treatment of acute leukemia since 1960. (ukessays.com)
  • Optimization of extracellular production of recombinant asparaginase in Escherichia coli in shake-flask and bioreactor. (springer.com)
  • Expression in Escherichia coli of a gene encoding type II l -asparaginase from Bacillus subtilis , and characterization of its unique properties. (springer.com)
  • Purified L-asparaginase II from Escherichia coli has been supplied and employed in the acute leukemia and other malignant neoplasms chemotherapy. (scialert.net)
  • Finally a semi-quantitative plate assay for L-asparaginase producing Escherichia coli is reported. (scialert.net)
  • Patients received topotecan (2.4 mg/m(2) daily as a 30-minute infusion) for 5 days before induction therapy with dexamethasone, vincristine, and asparaginase (native or pegylated Escherichia coli). (nih.gov)
  • L-asparaginase - enxyme derived from Escherichia coli. (vetstream.com)
  • Data from clinical trials suggest that polyethylene glycol‑conjugated asparaginase (PEG asparaginase) should be recommended as a replacement for Escherichia coli (E. coli) asparaginase in the treatment of pediatric acute lymphoblastic leukemia (ALL) due to its prolonged effect, similar safety profile and convenience. (spandidos-publications.com)
  • Polyethylene glycol-conjugated asparaginase (PEG asparaginase) is formed by the polyethylene glycosylation of the Escherichia coli ( E. coli )-derived enzyme, resulting in a longer circulating half-life and lower immunogenicity, which decreases the incidence of allergic reactions and anti-asparaginase antibody formation ( 12 , 13 ). (spandidos-publications.com)
  • L-asparaginase is an enzyme produced by Escherichia coli that catalyzes the conversion of L-asparagine to aspartic acid. (medscape.com)
  • 2016). 'Production and optimization of L-asparaginase in Escherichia coli ', Egyptian Journal of Botany , 56(1), pp. 203-224. (ekb.eg)
  • Asparaginase works by breaking down the amino acid known as asparagine without which the cancer cells cannot make protein. (wikipedia.org)
  • By adding asparaginase before baking or frying the food, asparagine is converted into another common amino acid, aspartic acid, and ammonium. (wikipedia.org)
  • Asparaginase, however, catalyzes the conversion of L-asparagine to aspartic acid and ammonia. (wikipedia.org)
  • Asparaginase kills cancer cells by depleting a certain protein in the blood (L-asparagine) that is necessary for survival and growth of tumor cells in patients with ALL. (encyclopedia.com)
  • Asparaginases (amidohydrolases, EC:3.5.1.1 ) are enzymes that catalyze the hydrolysis of asparagine to aspartic acid and ammonia. (ebi.ac.uk)
  • This entry represents type I L-asparaginases, which are highly specific for asparagine and localized in the cytosol [ PMID: 889890 ]. (ebi.ac.uk)
  • Many bacterial L-asparaginases have both L-asparagine and L-glutamine hydrolysis activities, to a different degree, and some of them are annotated as asparaginase/glutaminase [ PMID: 11996000 ]. (ebi.ac.uk)
  • The inhibition of the lymphosarcoma by asparaginase can be reversed by intraperitoneal injection of asparagine or glycine. (sciencemag.org)
  • Asparaginase (Erwinaze®) is an enzyme that breaks down (disassembles) the amino acid asparagine which is needed for cell maintenance and growth. (cancerquest.org)
  • By reducing free asparagine in the body, asparaginase treatment results in a depletion of cancerous cells while normal cells are more likely to be preserved. (cancerquest.org)
  • Asparaginase is an enzyme that speeds up the breakdown of asparagine in the blood into aspartic acid and ammonia. (oncolink.org)
  • In the assay, Asparaginase hydrolyzes asparagine to generate aspartic acid, which can be detected indirectly colorimetrically (OD=570 nm) or fluorescently (Ex/Em = 535/590 nm) using a coupled enzymatic reaction. (abcam.com)
  • Asparaginase (EC 3.5.1.1) is a homotetramer that catalyzes the hydrolysis of asparagine to aspartic acid and ammonia and exhibits about a 2-4% activity on glutamine and 5% on D-asparagine. (abcam.com)
  • Plant-type L-asparaginases hydrolyze the side-chain amide bond of L-asparagine or its beta-peptides. (rcsb.org)
  • Treatment of ALL includes the use of the bacterial enzyme asparaginase because of its ability to hydrolyze the amino acid l-asparagine in aspartic acid and ammonia, thus affecting leukemic blasts, which are generally incapable of producing asparagine by their own metabolism, unlike normal cells, which have asparagine synthetase. (scielo.br)
  • Asparaginase is an enzyme that breaks down asparagine. (roswellpark.org)
  • The mechanism by which asparaginase inhibits the 6C3HED tumor is probably not directly related to the cellular concentration of asparagine, since the concentration of asparagine decreases in resistant tumors, spleen, and liver, as well as in susceptible tumors. (aacrjournals.org)
  • Amino acids other than asparagine may be affected by asparaginase because of the variety of metabolic relationships of the amino acids. (aacrjournals.org)
  • L-asparaginase works by exploiting the unusually high requirement tumor cells have for the amino acid "asparagine. (marvistavet.com)
  • The enzyme L-Asparaginase destroys asparagine outside the cells forcing the cells to rely completely on what they can produce on their own. (marvistavet.com)
  • When L-asparaginase destroys asparagine, ammonia is a by-product. (marvistavet.com)
  • Result showed that mutation has no effect on the optimum pH and temperature of the enzyme while D90A catalytic efficiency values showed decreased of 21.9 % for asparagine and 119% lower catalytic efficiency for glutamine substrates in compare with the WT asparaginase. (ukessays.com)
  • Therefore, if these cells are treated with the L-asparaginase enzyme, they will be selectively eliminated because they are not able to replace the damaged L-asparagine amino acid without being harmed to healthy cells [2, 3]. (ukessays.com)
  • Intravenous injection of L-asparaginase reduces asparagine sources in the body and neoplastic cells are exposed to asparagine deficiency. (ukessays.com)
  • The asparaginase treatment quality relies on the fact that the cancer cells of the blood and other tumor cells are not able to produce asparagine, while healthy cells can do this naturally. (ukessays.com)
  • The role of L-asparaginase present in guinea pig serum in the reduction of lymphoma was first studied by Broome, and the inhibitory effect was attributed to depletion of asparagine due to the presence of L-asparaginase in the serum (2). (pharmtech.com)
  • L-asparaginase enzymatically cleaves amino acid L-asparagine into aspartic acid and ammonia. (pharmtech.com)
  • Normal cells, in contrast, are capable of synthesizing L-asparagine and are less affected by its rapid withdrawal during treatment with the enzyme L-asparaginase (4). (pharmtech.com)
  • Oncaspar is an asparagine-specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for treatment of patients with first line ALL and hypersensitivity to asparaginase. (pharmtech.com)
  • L-Asparagine in buffer (50 microM in 5 liters) was converted to L-aspartic acid within 60 min after circulation through a hemofilter containing 2000 I.U. of L-asparaginase. (biomedsearch.com)
  • Circulating L-asparagine in healthy sheep (about 40-50 microM was reduced to low levels after 2 to 3 hr of perfusion with a unit containing 2000 I.U. of L-asparaginase. (biomedsearch.com)
  • Contains 1-asparaginase amidohydrolase type EC-2, which inhibits protein synthesis by hydrolyzing asparagine to aspartatic acid and ammonia. (cancercare.ns.ca)
  • L-Asparaginase is an enzyme that depletes L-Asparagine "an important nutrient for cancer cells" resulting in cancer/tumor cell starvation. (biovendor.com)
  • Because of the lymph node origin of malignant B cells in Multiple Myeloma, L-Asparagine is an essential amino acid for their cell metabolism, and, consequently, L-Asparaginase may be of value in managing the disease. (biovendor.com)
  • The rationale behind asparaginase is that it takes advantage of the fact that ALL cellsare unable to synthesize the non-essential amino acidasparagine whereas normal cells are able to make their own asparagine. (biovendor.com)
  • This story includes the discovery of L-Asparaginase: The enzymatic deamination of asparagine was already studied by Clementi in 1922. (eur.nl)
  • 2 - 4 Asparaginase is a non-human enzyme which hydrolyses asparagine into aspartic acid and ammonia. (haematologica.org)
  • Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with PEG-Asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study. (haematologica.org)
  • Asparagine levels in cerebrospinal fluid and serum asparaginase activities were monitored in children with acute lymphoblastic leukemia treated with PEG-asparaginase. (haematologica.org)
  • Riccardi R, Holcenberg JS, Glaubiger DL, Wood JH, Poplack DG (1981) L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. (springermedizin.de)
  • L-ase kills leukemic cells by depleting circulating asparagine pools related to its asparaginase activity [2]. (semanticscholar.org)
  • Asparaginase (as par' a jin ase), often referred to as L-asparaginase, is a bacterial enzyme that acts to decrease tissue stores of asparagine, a secondary amino acid that is important in the growth of many cancers. (wikimd.org)
  • Asparaginase hydrolyses asparagine to aspartic acid and ammonia. (galenreasoner.com)
  • As a result of asparaginase-induced asparagine depletion in serum, protein synthesis in lymphoblastic tumour cells is disturbed while sparing most normal cells. (galenreasoner.com)
  • Asparaginase (EC 3.5.1.1, USAN) or Colaspase (BAN) is an enzyme that catalyzes the hydrolysis of asparagine (Asn) to aspartic acid. (kerafast.com)
  • Asparagine specific enzymes, also known as asparaginase, are derived from bacteria. (cchmedicalpolicies.com)
  • Asparaginase works by depleting blood plasma levels of asparagine, an amino acid necessary for cellular function. (cchmedicalpolicies.com)
  • Pegaspargase is L-asparaginase (L-asparagine amidohydrolase) that is conjugated to monomethoxypolyethylene glycol (mPEG). (cchmedicalpolicies.com)
  • Normal cells, however, are able to synthesize asparagine and thus are affected less by the rapid depletion produced by treatment with the enzyme asparaginase. (pharmacycode.com)
  • The study examines how asparaginase which deplete asparagine, a critical amino acid, help fight leukemia in three patients. (jkzx.com)
  • One mole of aspartate corresponds to one mole of asparagine metabolized by asparaginase. (assaygenie.com)
  • Kit can be used to detect Asparaginase enzyme's antineoplastic effects, based on the inability of cancer cells (unlike healthy cells) to synthesize asparagine. (assaygenie.com)
  • One of the E. coli asparaginases marketed under the brand name Elspar for the treatment of acute lymphoblastic leukemia (ALL) is also used in some mast cell tumor protocols. (wikipedia.org)
  • tell your doctor if you have or have ever had pancreatitis (swelling of the pancreas), blood clots, or severe bleeding, especially if these happened during treatment with asparaginase (Elspar) or pegaspargase (Oncaspar). (medlineplus.gov)
  • Asparaginase (also known as L-asparaginase, and sold under the brand name Elspar) is a medicine used to stop growth of cancer and formation of new cancer cells. (encyclopedia.com)
  • Elspar asparaginase is a drug for the treatment of acute lymphoblastic leukemia [11, 12]. (ukessays.com)
  • Also called Elspar and L-asparaginase. (wikimd.org)
  • This native form of asparaginase, marketed as Elspar, is no longer commercially available in the United States (U.S). (cchmedicalpolicies.com)
  • Spectrila is a new recombinant E. coli asparaginase. (wikipedia.org)
  • The standard source is called E. coli Asparaginase, which is associated with a risk of allergic reactions. (clinicaltrials.gov)
  • In children there is some early information that PEG-Asparaginase produces fewer antibodies than E.coli Asparaginase. (clinicaltrials.gov)
  • The disadvantage of frequent intramuscular injections and the adverse events of hypersensitivity reactions led to development of a pegylated version of native E. coli -asparaginase (polyethylene glycol [PEG]-asparaginase: Oncaspar, Enzon Pharmaceuticals Inc) (9). (pharmtech.com)
  • Simulated scenarios (decision tree analysis) using native E. coli asparaginase in intensification showed that the costs of PEGasparaginase were equal to those of native E. coli asparaginase. (haematologica.org)
  • Also after sensitivity analyses, the costs for PEGasparaginase were equal to those of native E. coli asparaginase. (haematologica.org)
  • PEGasparaginase is preferred over native E. coli asparaginase, because it is administered less frequently, with less day care visits. (haematologica.org)
  • PEGasparaginase is less immunogenic than native E. coli asparaginase and is not more expensive. (haematologica.org)
  • The clinical data of 122 patients, ≥14 years old with de novo ALL, who received either PEG asparaginase or E. coli asparaginase as part of an induction regimen, were retrospectively analyzed. (spandidos-publications.com)
  • The results revealed that PEG asparaginase had a comparable complete remission rate (95.65 vs. 90.79%), median overall survival time (14.07 vs. 16.29 months) and median relapse‑free survival time (10.00 vs. 8.57 months) with E. coli asparaginase. (spandidos-publications.com)
  • PEG asparaginase has been recommended as a replacement for E. coli asparaginase in the treatment of pediatric ALL due to its prolonged effect, similar safety profile and convenience ( 14 ). (spandidos-publications.com)
  • In addition, considering the decreased number of doses and clinic visits, the total patient costs of PEG asparaginase are comparable with those of native E. coli asparaginase ( 15 ). (spandidos-publications.com)
  • However, only a few clinical studies have compared the efficacy and safety of PEG asparaginase with native E. coli asparaginase in adolescent and adult patients with ALL. (spandidos-publications.com)
  • The present study retrospectively compared the relative efficacy and safety of PEG asparaginase and E. coli asparaginase in adolescent and adult patients newly diagnosed with ALL. (spandidos-publications.com)
  • A total of 122 patients who were ≥14 years old with de novo ALL and had received treatment at the Department of Hematology, Nanfang Hospital (Guangzhou, China) between January 2008 and July 2015 were included in this retrospective study, including 46 patients in the PEG asparaginase group and 76 in the E. coli asparaginase group. (spandidos-publications.com)
  • Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia. (onmedica.com)
  • We evaluated the prevalence of antibodies against PEG among patients with acute lymphoblastic leukemia (ALL) prior to and/or immediately after their first dose of pegylated E.coli asparaginase (PEG-ASNase). (onmedica.com)
  • Serum samples were collected for estimating the pharmacokinetic parameters of each patient during native E. coli asparaginase therapy. (springermedizin.de)
  • Challenges with native E. coli asparaginase were successful, and asparaginase serum concentrations above therapeutic levels were attained in both patients. (springermedizin.de)
  • These two cases suggest that some patients can be given native E. coli asparaginase after hypersensitivity reactions to PEGylated asparaginase and achieve therapeutic concentrations of the drug in serum. (springermedizin.de)
  • Woo MH, Hak LJ, Storm MC, Evans WE, Sandlund JT, Rivera GK, Wang B, Pui CH, Relling MV (1998) Anti-asparaginase antibodies following E . coli asparaginase therapy in pediatric acute lymphoblastic leukemia. (springermedizin.de)
  • As a medication, L-asparaginase is used to treat acute lymphoblastic leukemia (ALL). (wikipedia.org)
  • Asparaginase is used as part of an induction regimen for the treatment of acute lymphocytic leukemia (ALL) in children. (encyclopedia.com)
  • Asparaginase is used to treat acute lymphocytic leukemia (ALL). (webmd.com)
  • Other asparaginases are used to treat acute lymphoblastic leukemia (ALL) and some other hematopoietic neoplasms (e.g. multiple myeloma). (abcam.com)
  • Treatment Of Newly Diagnosed Adult Acute Lymphoblastic Leukemia With Intensified Post Remission Therapy Containing PEG-Asparaginase. (clinicaltrials.gov)
  • Bacterial asparaginases (amidohydrolases, EC 3.5.1.1) are important enzymes in cancer therapy, especially for Acute Lymphoblastic Leukemia. (mdpi.com)
  • l-Asparaginase is a key therapeutic agent for treatment of childhood acute lymphoblastic leukemia (ALL). (jci.org)
  • Erwinaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli -derived asparaginase 1 . (prnewswire.co.uk)
  • Although it is an essential component of the treatment of acute lymphoid leukemia in children, asparaginase causes adverse reactions that sometimes make it impossible to use it fully. (scielo.br)
  • L-asparaginase (L-ASNase) is FDA approved enzyme which is widely used in pharmacy for treatment of acute lymphoblastic leukemia. (ukessays.com)
  • The L-asparaginase enzyme is an important factor in chemotherapy that is used for acute lymphoblastic leukemia (ALL) [7, 8]. (ukessays.com)
  • L-asparaginase has been extensively investigated for the treatment of acute lymphoblastic leukemia (ALL) (1). (pharmtech.com)
  • Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. (springer.com)
  • Asparaginase is a prescription medicine approved for use with other chemotherapy drugs to treat a certain type of acute lymphocytic leukemia (ALL is a type of cancer of the white blood cells). (rxwiki.com)
  • Acute lymphoblastic leukemia (L3) was initially diagnosed because of poor staining of alpha-naphtyl butylate esterase and induction chemotherapy with the LVP regimen (L-asparaginase 5,000 U/m2 day 8-21, vincristine 1.5 mg/ m2 day 1, 6, 11, 16, 21, 26, prednisolone 40 mg/m2 day 1-28) was performed. (unboundmedicine.com)
  • Asparaginase is an expensive drug, but important in childhood acute lymphoblastic leukemia. (haematologica.org)
  • Asparaginase-associated pancreatitis is a life-threatening toxicity to childhood acute lymphoblastic leukemia treatment. (haematologica.org)
  • To elucidate genetic predisposition and asparaginase-associated pancreatitis pathogenesis, ten trial groups contributed remission samples from patients aged 1.0−17.9 years treated for acute lymphoblastic leukemia between 2000 and 2016. (haematologica.org)
  • Asparaginase is one of the major anticancer drugs used in the treatment of acute lymphoblastic leukemia (ALL) ( 1 , 2 ). (spandidos-publications.com)
  • Asparaginase (ASNase) is an essential component of most treatment protocols for childhood acute lymphoblastic leukemia (ALL). (nih.gov)
  • L-Asparaginase has significantly improved outcome for children with acute lymphoblastic leukemia and has become an essential component of multiagent chemotherapy. (ovid.com)
  • However, there are many adverse events due to L-asparaginase, including acute pancreatitis. (ovid.com)
  • We prospectively studied the incidence and clinical course of hypertriglyceridemia and hypercholesterolemia during very prolonged use of asparaginase in relation to levels of asparaginase activity in children with acute lymphoblastic leukemia. (eur.nl)
  • Asparaginase is an essential component of pediatric acute lymphoblastic leukemia (ALL) therapy. (springermedizin.de)
  • Raetz EA, Salzer WL (2010) Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. (springermedizin.de)
  • Differential mechanisms of asparaginase resistance in B-type acute lymphoblastic leukemia and malignant natural killer cell lines. (cnrs.fr)
  • Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors. (semanticscholar.org)
  • asparaginase (as-PAYR-uh-jih-NAYS) is a drug that is used to treat acute lymphoblastic leukemia (ALL) and is being studied in the treatment of some other types of cancer . (wikimd.org)
  • Asparaginase is a bacterial enzyme that is used as an antineoplastic agent, largely in the therapy of acute lymphocytic leukemia . (wikimd.org)
  • Asparaginase, prepared from E. coli, was introduced into cancer chemotherapy over 50 years ago and remains an important agent in the therapy of acute lymphocytic leukemia . (wikimd.org)
  • acute myelogenous leukemia (AML) Cell culture and mouse studies suggest inhibiting GSK3A could help treat asparaginase-resistant T cell and B cell ALL and AML. (biocentury.com)
  • In two patients with advanced acute lymphatic leukemia, the therapy with the enzyme L-asparaginase improved their conditions significantly. (jkzx.com)
  • 11/18/2011: Initial FDA approval "as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase . (hemonc.org)
  • Usually the side effects of asparaginase are more severe in adults than in children. (encyclopedia.com)
  • There are a number of things you can do to manage the side effects of asparaginase. (oncolink.org)
  • Common side effects of asparaginase include serious hypersensitivity reactions, nausea, vomiting, and elevated blood sugar levels. (rxwiki.com)
  • Unlike most of other chemotherapy agents, asparaginase can be given as an intramuscular, subcutaneous, or intravenous injection without fear of tissue irritation. (wikipedia.org)
  • Intramuscular injection of asparaginase lowers the risk of severe allergic reactions (also known as hypersensitivity or anaphylaxis). (encyclopedia.com)
  • Asparaginase is given by intravenous (into a vein) infusion or as an injection given into a big muscle (called intramuscular or IM). (oncolink.org)
  • Standard asparaginase is given either by intramuscular injection or, more typically, intravenous injection in doses of 25,000 IU/m2 three times weekly in 14 day cycles. (wikimd.org)
  • Normal asparaginase costs less than its pegylated version, pegaspargase. (wikipedia.org)
  • It is important to address manufacturing problems associated with the shorter shelf-life of pegylated L-asparaginase (pegaspargase) upon long-term storage in the form of a solution. (pharmtech.com)
  • Do not receive asparaginase if you are allergic to asparaginase or pegaspargase ( Oncaspar ). (rxwiki.com)
  • Pegylated formulations of E. coli-derived asparaginase (pegaspargase) became available and were approved for use in 1994. (wikimd.org)
  • Pegaspargase, also referred to as PEG-L-asparaginase, pegylated asparaginase (PEG-ASP), and PEG-asparaginase, was initially approved by the FDA in 1994 for individuals with ALL and hypersensitivity to native asparaginase. (cchmedicalpolicies.com)
  • Because pegaspargase is pegylated, it lasts longer and causes less hypersensitivity than native asparaginase (Avramis, 2002). (cchmedicalpolicies.com)
  • Primary Examiner-Lionel M. Shapiro Attorney-Craig, Antonelli and Hill ABSTRACT: The antitumor activity of L-asparaginase produced from the cultured cells of micro-organisms belonging to the genus Serratia is retained by a purification process wherein, as one of the steps in the purification procedure, the enzymatic liquid is heated to a temperature of at least 60C. (google.com)
  • Branded formulations (with different chemical and pharmacological properties) available in 1998 include Asparaginase Medac, Ciderolase, and Oncaspar. (wikipedia.org)
  • Therefore, another purpose of the study is to see how many adult patients who receive PEG-Asparaginase develop antibodies against the drug. (clinicaltrials.gov)
  • We offer L-Asparaginase Antibodies for use in common research applications: ELISA, Immunoprecipitation, Western Blot. (novusbio.com)
  • Our L-Asparaginase Antibodies can be used in a variety of model species: Bacteria. (novusbio.com)
  • Choose from our L-Asparaginase polyclonal antibodies. (novusbio.com)
  • Allergic hypersensitivity reactions impair the continuity of treatment with the type of l-asparaginase adopted, since inactivation of the enzyme may occur due to the formation of anti-asparaginase immunoglobulin IgG and IgE antibodies, making its use risky and ineffective. (scielo.br)
  • Although L-asparaginase is an effective antineoplastic agent used in chemotherapy of ALL, development of antibodies against L-asparaginase and hypersensitivity reactions may lead to discontinuation of the treatment (6). (pharmtech.com)
  • Silent inactivation is the formation of anti-asparaginase antibodies which neutralize asparaginase without their being clinical symptoms of an allergy. (haematologica.org)
  • Asparaginase (Erwinaze®) is administered through use of a powder that is to be mixed and injected intravenously or directly into a muscle. (cancerquest.org)
  • The purpose of the study is to find out what side effects occur in adults when PEG-Asparaginase is given with other chemotherapy drugs and to see what effect it has on the response to treatment of ALL. (clinicaltrials.gov)
  • Asparaginase treatment is recommended as an important component of a multi-agent chemotherapy regimen in ALL 6 . (prnewswire.co.uk)
  • Toxicity of vincristine another chemotherapy agent, may be more likely if vincristine and L-asparaginase are given at the same time. (marvistavet.com)
  • L-asparaginase (L-ASP) is a well-known and prominent growth inhibitory enzyme in oncology clinics and has been successfully used for combination chemotherapy in ALL and some solid tumours [ 5 ]. (ijpsonline.com)
  • Once the disease is in its advanced stages, there is no standard treatment but one recent regime involving treatment with the enzyme asparaginase combined with radiotherapy or chemotherapy seems to be promising. (separationsnow.com)
  • Blood was taken from two sets of patients diagnosed with stage III or IV ENKTL, those who responded to asparaginase/chemotherapy and those who did not. (separationsnow.com)
  • Clinical data, including the patients' characteristics, response to chemotherapy and adverse effects experienced in association with asparaginase preparations, were retrospectively analyzed. (spandidos-publications.com)
  • Both standard and pegylated asparaginase are usually given in combination with other antineoplastic agents such as vincristine, mercaptopurine, methotrexate, daunorubicin, and prednisone. (wikimd.org)
  • Asparaginase belongs to class of medications called antineoplastic agents. (heethealthcare.co.in)
  • Type I L-asparaginase protein may use the morpheein model of allosteric regulation. (wikipedia.org)
  • Site-directed mutagenesis of Rhodospirillum rubrum l -asparaginase (RrA) was performed in order to identify sites of the protein molecule important for its therapeutic and physico-chemical properties. (springer.com)
  • So, higher levels of this protein indicate a poor response to asparaginase treatment. (separationsnow.com)
  • Decreased AT and fibrinogen levels resulting from the strong suppression of protein synthesis by L-asparaginase were predictive signs for AAP. (ovid.com)
  • L-asparaginase has many side effects , one of which is hepatic injury that is characterized by inhibition of hepatic protein synthesis and steatosis, which can be severe and lead to death from hepatic failure. (wikimd.org)
  • The human asparaginase-like protein 1 hASRGL1 is an Ntn hydrolase with beta-aspartyl peptidase activity. (nih.gov)
  • Cell growth stimulation by CRASH, an asparaginase-like protein overexpressed in human tumors and metastatic breast cancers. (nih.gov)
  • A cDNA sequence encoding the sequence of L-Asparaginase was constructred and used to recombinantly synthesize the protein. (enquirebio.com)
  • Asparaginase is mainly given in combination with vincristine and steroids (either prednisone or dexamethasone ) for the first three weeks of therapy. (encyclopedia.com)
  • Asparaginase should be given after vincristine instead of before or with vincristine because it can increase the risk of numbing, tingling and pain in hands and feet. (encyclopedia.com)
  • We also evaluated the incidence of pancreatitis, thrombosis, hyperammonemia and central neurotoxicity and their association with asparaginase activity levels. (eur.nl)
  • Manhattan plot of P values for genome-wide SNP association with asparaginase hypersensitivity. (cdc.gov)
  • A) The Manhattan plot shows the negative log10 of the P values for association with asparaginase hypersensitivity vs each chromosome on the x-axis. (cdc.gov)
  • In this country, two forms of asparaginase are available: one made from E. coli, and a slightly changed version of the E.Coli form linked to polyethylene glycol (PEG) molecule. (encyclopedia.com)
  • The use of this medication should be avoided in patients with active pancreatitis (inflammation of the pancreas) or history of pancreatitis, and in patients with serious allergic reaction to asparaginase in the past. (encyclopedia.com)
  • Used in some patients who have had a hypersensitivity reaction to another form of asparaginase. (chemocare.com)
  • One of the drugs, which is typically given to patients with ALL, is called Asparaginase. (clinicaltrials.gov)
  • The intravenous administration trial was conducted at 10 centers in the U.S. and recruited a total of 30 patients, of which 24 patients were evaluable for the primary endpoint, which was the proportion of patients having an asparaginase activity level of greater than 0.1 IU/mL 48 hours after dosing 1, 2 . (prnewswire.co.uk)
  • L-asparaginase may interfere with blood clotting, may raise blood sugar levels, may raise liver enzyme blood tests, and may cause liver disease in some patients. (marvistavet.com)
  • To test if intramuscular PEG-asparaginase administered either at six or two week intervals from day 92 until 8 months from diagnosis for patients with non-HR ALL will result in equal probability of EFS. (clinicaltrials.gov)
  • Terebelo H. Thrombosis in patients treated with L-asparaginase. (jaoa.org)
  • It could be used as an indicator of patients who would not respond well to treatments based on asparaginase, allowing clinicians to adopt different, more aggressive strategies that might afford more positive results. (separationsnow.com)
  • Adolescent and adult patients receiving pediatric-based regimens with greater use of asparaginase have also achieved better outcomes ( 8 - 10 ). (spandidos-publications.com)
  • However, they are more prone to severe grade 3-4 toxicities, including thrombosis, pancreatitis and chemical hepatitis, compared with pediatric patients intensively using asparaginase ( 11 ). (spandidos-publications.com)
  • Cerebral venous sinus thrombosis is a well-recognised complication in patients with T-lymphoblastic lymphoma/T-lymphoblastic leukaemia receiving L-asparaginase, with an ongoing risk outside the induction period. (bmj.com)
  • The discovery and development of asparaginase as an anti-cancer drug began in 1953, when scientists first observed that lymphomas in rat and mice regressed after treatment with guinea pig serum. (wikipedia.org)
  • It took until 1961 before an explanation was found for these observations: Broome, working in Kidd's laboratory, presented evidence that the enzyme L-Asparaginase was responsible for the antitumor activity of guineapig serum. (eur.nl)
  • (c) Reaction kinetics of asparaginase activity in human serum spiked with various amounts of asparaginase from E. coli. (assaygenie.com)
  • Pooled normal serum (each 5 μl per well) spiked with 0, 20, 80 or 160 mU/ml of asparaginase was assayed in colorimetric mode according to the kit protocol. (assaygenie.com)
  • Serious allergic reactions can occur in people who receive asparaginase. (rxwiki.com)
  • 2006). Asparaginase production by a recombinant Pichia pastoris strain harbouring Saccharomyces cerevisiae ASP3 gene. (springer.com)
  • PEG-asparaginase (1.000 IU/m2/dose) given at six weeks intervals (from week 13 after diagnosis to week 33). (clinicaltrials.gov)
  • Additionally, a single pretreatment dose of erythrocyte-binding asparaginase tolerized mice to multiple subsequent doses of the wild-type enzyme. (sciencemag.org)
  • Triglyceride, cholesterol and ammonia levels increased rapidly in children treated with PEGasparaginase and remained temporarily elevated, but normalized after administration of the last asparaginase dose. (eur.nl)
  • During cycle 3 consolidation, 10 days following the last dose of pegylated-asparaginase, she presented with refractory generalised tonic-clonic seizures requiring induction of anaesthesia, intubation and mechanical ventilation. (bmj.com)
  • Dyslipidemia was the only toxicity related to levels of asparaginase activity. (eur.nl)
  • Asparaginase katalysiert die Hydrolyse von L-Asparagin und bewirkt auf diese Weise eine Depletion des Asp. (uni-marburg.de)
  • Each L-Asparaginase Antibody is fully covered by our Guarantee+, to give you complete peace of mind and the support when you need it. (novusbio.com)
  • Asparaginase, also known as L-asparaginase or ASNase, was approved by the U.S. Food and Drug Administration (FDA) in 1978 for a main component of ALL first-line therapy and refractory disease regimens. (cchmedicalpolicies.com)
  • Prednisolone tends to raise blood sugar levels to a greater extent when used in combination with L-asparaginase. (marvistavet.com)
  • Antiproliferative and apoptotic effects of pterostilbene were examined in combination with L-asparaginase in Jurkat cell line. (ijpsonline.com)
  • Jurkat cells were incubated with different concentrations of pterostilbene alone or in combination with L-asparaginase for 24, 48 and 72 h. (ijpsonline.com)
  • The antitumor activity of L-asparaginase produced from the cultured cells of micro-organisms belonging to the genus Serratia is retained by a purification process wherein, as one of the steps in the purification procedure, the enzymatic liquid is heated to a temperature of at least 60* C., preferably 6070* C., thereby denaturing and rendering ineffective the L-asparaginaseinactivating factors contained in the liquid. (google.com)
  • The mechanisms of therapeutic failure with l-asparaginase remain speculative. (jci.org)
  • Findings provide a rationale for testing the hypothesis that a glutaminase-deficient asparaginase variant (D90A) will exhibit greater therapeutic index than that of WT against cancers and could be used in therapeutic drug development research. (ukessays.com)
  • Humoral immune tolerance to the therapeutic enzyme E. coli l -asparaginase was induced by engineering the enzyme for in vivo erythrocyte binding. (sciencemag.org)
  • L -ASPARAGINASE (L-ASNase) has been widely used as a therapeutic agent in the treatment of various lymphoblastic leukemia diseases. (ekb.eg)
  • L-asparaginase is a homotetrameric enzyme comprised of four identical subunits with a mass of 34,592 Da coupled by weak, non-covalent, largely hydrophobic interactions (10). (pharmtech.com)
  • No asparaginase drug interactions have been identified, however, you should tell your doctor about all the medicines you take including prescription and non-prescription medicines, vitamins, and herbal supplements. (rxwiki.com)
  • ASRGL1 exhibits beta-aspartyl peptidase activity consistent with plant-type asparaginases. (nih.gov)
  • There are several forms of asparaginase, made from different bacteria and your care team will determine which type is best for you. (oncolink.org)
  • Asparaginase does not occur naturally in humans but is found in bacteria, plants and many animals (e.g. guinea pigs). (abcam.com)
  • L-asparaginase is an enzyme produced by bacteria. (marvistavet.com)
  • Asparaginase is normally derived from E. coli bacteria. (marvistavet.com)
  • The objective of this study was to isolate halophilic bacteria with the ability to produce intracellular or extracellular L-asparaginase. (ac.ir)
  • Asparaginase belongs to a group of drugs called enzymes. (rxwiki.com)
  • Asparaginase is one of the key drugs in this treatment. (haematologica.org)
  • The implementation of the differential diagnosis of reactions related to infusion of asparaginase with ammonia dosage and classification of the grade of reactions is crucial to facilitate the identification and proper management of each type of reaction. (scielo.br)
  • L-Asparaginase Activity in Cell Lysates and Culture Media of Halophilic Bacterial Isolates', Iranian Journal of Pharmaceutical Research , 15(3), pp. 435-440. (ac.ir)
  • In this study, a different form of Asparaginase will be used, called PEG-Asparaginase (also called Oncospar), which remains in the body for about two weeks, therefore, it can be given only once in a cycle of treatment and still maintains high blood levels of the drug. (clinicaltrials.gov)
  • In children it was found to be as safe as the standard form of Asparaginase and with less allergic reaction. (clinicaltrials.gov)
  • Asparaginase can be given in various dosing schedules, depending on the regimen and the type of asparaginase being used. (oncolink.org)
  • Do not take this drug if you are allergic to asparaginase or any of its ingredients. (indmed.in)
  • None of the isolates appeared to produce appreciable amounts of extracellular L-asparaginase. (ac.ir)
  • Asparaginase was incorporated into the treatment of ALL in the 1970s as an essential component of induction regimens and consolidation of remission in pediatric ALL. (scielo.br)
  • Asparaginase medac, Kyowa Hakko) has been used in the treatment of ALL (5). (pharmtech.com)
  • Clinicians would benefit greatly if they knew in advance whether or not asparaginase treatment is going to be effective so that they can adjust the regime accordingly. (separationsnow.com)
  • Mingzhi Zhang and colleagues from the First Affiliated Hospital of Zhengzhou University used proteomics techniques to identify prognostic biomarkers for the outcome of asparaginase treatment and came up with a very strong candidate. (separationsnow.com)
  • One of the differences between pediatric and adult treatment regimens is the intensive use of asparaginase in pediatric regimens. (spandidos-publications.com)
  • In conclusion, severe dyslipidemia occurred frequently, but was temporary and was not associated with relevant clinical events and should not, therefore, be considered a reason for modifying asparaginase treatment. (eur.nl)
  • However, asparaginase-induced hypersensitivity reactions can compromise its efficacy either by directly influencing the pharmacokinetics of asparaginase or by leading to a discontinuation of asparaginase treatment. (springermedizin.de)
  • Is N-acetylcysteine infusion an effective treatment option in L-asparaginase associated hepatotoxicity? (semanticscholar.org)
  • Structures of apo and product-bound human L-asparaginase: insights into the mechanism of autoproteolysis and substrate hydrolysis. (nih.gov)
  • Asparaginase treats a certain type of leukemia. (rxwiki.com)
  • To screen for anticancer activity, we found that 68% of all isolated actinobacteria produced L-asparaginase, which is a hydrolytic enzyme that acts as an inhibitor of leukemia. (microbiologyresearch.org)
  • These side effects mainly attributes to the dual activity of L.Asparaginase as it can also hydrolysis L.Glutamine to Glutamic acid and ammonia Acrylamide is often formed in the cooking of starchy foods. (wikipedia.org)
  • One example of an enzyme with no L-glutaminase activity is the type I L-asparaginase from Wolinella succinogenes [ PMID: 8898907 ]. (ebi.ac.uk)
  • Sequence analysis of enzymes with asparaginase activity. (ebi.ac.uk)
  • Asparaginase Activity Assay Kit (Colorimetric/Fluorometric) (ab107922) provides a simple, direct and automation-ready procedure for measuring asparaginase activity in biological samples. (abcam.com)
  • Glucose was exhausted two hours before ammonia and three hours before asparaginase II activity was detected. (unt.edu)
  • Culture tube studies of the growth of E_j_ coli A-l in three per cent nutrient broth with varied concentrations of ammonium chloride and potassium nitrate gave lower specific activity of asparaginase II when this was compared to that seen in three per cent nutrient broth alone. (unt.edu)
  • however, addition after L-asparaginase synthesis had started did not affect the specific activity of the enzyme. (unt.edu)
  • The tetrameric structure of the L-asparaginase enzyme is required for enzymatic activity (11). (pharmtech.com)
  • To improve efficiency of A. niger asparaginase in application, we applied directed evolution to optimize the pH-activity profile of the enzyme. (aspergillus.org.uk)
  • Overall yield of the active enzymes was 70-80 %, their specific activity at pH 7.4 and 37 °C varied of 140-210 U/mg. l -Glutaminase activity did not exceed 0.01 % of l -asparaginase activity. (springer.com)
  • these toxicities were not related to levels of asparaginase activity or to triglyceride levels. (eur.nl)
  • Among the isolates that produced intracellular L-asparaginase, 5 moderate and 1 extreme halophiles were selected for further study based on their observed activity level. (ac.ir)
  • ALP03 was among the active isolates exhibited the highest enzyme activity of L-asparaginase and showed a maximum 97.93 % similarity of its 16S rRNA gene sequence to Streptomyces spongiae Sp080513SC-24T. (microbiologyresearch.org)
  • The cytotoxicity assays against diverse types of cancer cell lines will be carried out to assess the anticancer potential of isolate ALP03 and the others showing distinct L-asparaginase activity. (microbiologyresearch.org)
  • Asparaginase has activity against other cancer types, but is rarely used for other indications. (wikimd.org)
  • Has both L-asparaginase and beta-aspartyl peptidase activity. (nih.gov)
  • One of the most widely used enzymes in the medical industry and food industry is the L-asparaginase enzyme [1]. (ukessays.com)
  • or where serious pancreatitis, serious thrombosis or serious hemorrhagic events occurred with prior L-asparaginase therapy. (prnewswire.co.uk)
  • Such adverse events along with the other toxicities like thrombosis, pancreatitis, hyperglycemia, and hepatotoxicity led to the development of alternative sources of L-asparaginase (7). (pharmtech.com)
  • Asparaginase can decrease effectiveness of methotrexate in killing cancer cells when given right before and together with methotrexate. (encyclopedia.com)
  • L-asparaginase and methotrexate work against each other and should be administered at least 48 hours apart. (marvistavet.com)
  • E. coli strains are the main source of medical asparaginase. (wikipedia.org)
  • The report Medical Asparaginase Market Analysis and forecast 2024 maintains enhanced dynamics and is overshadowed by a top player across the globe. (phanaticmag.com)
  • The research report provides Medical Asparaginase Market analysis and information corresponding to market segments such as geographies, product type, application, and end-use industry. (phanaticmag.com)
  • Experts use the most recent Medical Asparaginase Market research techniques and tools to assemble widespread and precise marketing research reports. (phanaticmag.com)
  • A detailed outline about Medical Asparaginase market size and share were combined in this report which gives a comprehensive analysis of different verticals of businesses. (phanaticmag.com)
  • The Medical Asparaginase Market forecast report could be a collection of first-hand info, qualitative and quantitative assessment by Medical Asparaginase industry analysts, and industry participants across business area. (phanaticmag.com)
  • As per the latest report added by Market Study Report LLC, the overall Medical Asparaginase market size, have been registered at 390 Million in 2019, is projected to witness a growth rate of close to 1.5 %, and is likely to cross a valuation of 430 Million by the year 2024. (phanaticmag.com)
  • The Medical Asparaginase Market report provides effective guidelines and strategies for industry players to obtain a position at the top in the Medical Asparaginase Market. (phanaticmag.com)
  • Also, this report is highlighting worldwide and leading key players profiles and serves the eventual guide to discovering opportunities in the Medical Asparaginase Market industry globally. (phanaticmag.com)
  • By implementing several top-down and bottom-up approaches on the historical sales & revenue data and the current Medical Asparaginase market status, the researchers have forecasted the Medical Asparaginase market growth and size in key regions. (phanaticmag.com)
  • The significant applications and prospective business arenas are also added to Medical Asparaginase Market outlook report. (phanaticmag.com)
  • Apart from exploring into the various segments, the report clustered on key Medical Asparaginase Market trends and sectors that are either driving or averting the growth of the Medical Asparaginase industry. (phanaticmag.com)
  • The Medical Asparaginase Market industry development trends are studied through both secondary and primary sources. (phanaticmag.com)
  • Finally, the feasibility of the latest investment comes is assessed and overall analysis conclusions offered in Medical Asparaginase market analysis report. (phanaticmag.com)
  • Factors in relation to products like the products prototype, manufacturing method, and r&d development stage are well-explained in the global Medical Asparaginase Market research report with point-to-point structure and with tables and figures. (phanaticmag.com)
  • The report covers the major driving factors influencing the revenue scale of the Medical Asparaginase market and details about the rising demand for the product from the key geological regions. (phanaticmag.com)
  • The Medical Asparaginase market analyst pot light on different approaches to discover the strengths, weaknesses, opportunities, and threats affecting the growth of the global Medical Asparaginase Market. (phanaticmag.com)
  • What is the process to get company portfolio of top players of Medical Asparaginase Market? (phanaticmag.com)
  • What will be the market worth of the Global Medical Asparaginase Market in next few years? (phanaticmag.com)
  • Which are the well-recognized companies in Medical Asparaginase Market? (phanaticmag.com)
  • Induction of L-asparaginase synthesis in Vibrio proteus. (bvsalud.org)
  • Since asparaginase has dual asparaginase and glutaminase activities with high affinity to glutamine which catalyzes the hydrolysis of glutamine to glutamate and NH3, this reaction will leads to decreases glutamine and increase NH3 in blood with toxic effect. (ukessays.com)
  • Asparaginase and glutaminase activities of micro-organisms. (semanticscholar.org)
  • Many studies have shown that intensification by asparaginase is essential to improve the event-free survival of children with ALL. (haematologica.org)
  • Intensified use of asparaginase increases event-free survival (EFS) for children with ALL by 10-15% ( 5 - 7 ). (spandidos-publications.com)
  • The use of L-asparaginase has been associated with pancreatitis . (marvistavet.com)
  • Inflammation of the pancreas (pancreatitis), sometimes severe or causing death, can occur with asparaginase therapy. (rxwiki.com)
  • Controls (n=1320) completed intended asparaginase therapy, with 78% receiving ≥8 injections of pegylated-asparaginase, without developing asparaginase-associated pancreatitis. (haematologica.org)
  • P =1.1×10 −5 ) on 7q34 showed significant association with the risk of asparaginase-associated pancreatitis. (haematologica.org)
  • The pathology of L-asparaginase-associated pancreatitis (AAP) remains unclear. (ovid.com)
  • Schalk AM, Nguyen HA, Rigouin C, Lavie A. Identification and structural analysis of an L-asparaginase enzyme from guinea pig with putative tumor cell killing properties. (kerafast.com)